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ABSTRACT 
The rapid emergence of bacteria that are resistant to today’s antibiotics makes 
them more and more ineffective.  Consequently, the need for a novel class of antibacterial 
agents is rapidly increasing.  The importance of this project is emphasized by the 
emergence of several pathogenic bacterial strains that are resistant to all currently 
available antibiotics on the market today.  One way to approach this problem is to 
develop drugs that target essential bacterial biosynthetic pathways.  Based on bacterial 
genetic information, the meso‐diaminopimelate (mDAP)/lysine biosynthetic pathway 
offers several potential anti‐bacterial targets that have not been yet explored.  One of 
these, the dapE-encoded N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) 
catalyzes the hydrolysis of N-succinyl-L,L-diaminopimelate to L,L-diaminopimelate and 
succinate.  Since there are no similar pathways in mammals, inhibitors that target one or 
more of the enzymes in the mDAP/lysine biosynthetic pathway will likely exhibit 
selective toxicity against only bacteria. 
It has been shown experimentally that deletion of the gene encoding for DapE is 
lethal to Helicobacter pylori and Mycobacterium smegmatis.  Therefore, DapEs are 
crucial for bacterial cell growth and proliferation, making them potential targets for a new 
class of antibiotics.  Rational design of inhibitors for DapE relies on understanding the 
active site structure and catalytic mechanism.  Therefore, the DapE enzymes from 
Haemophilus influenzae and Neisseria meningitidis were characterized biochemically and 
 xvii 
crystallographically.  In addition, residues situated within the active site were mutated 
and the mutated enzymes were characterized via kinetic and crystallographic methods in 
order to gain insight into substrate binding.  In order to examine the role of the catalytic 
domain of DapE truncated enzymes from Vibrio cholera and H. influenzae were 
engineered by deleting their dimerization domains.  And finally, a reliable and 
reproducible spectrophotometric assay for DapE enzymes that is conducive to high-
throughput screening was developed. 
1 
CHAPTER ONE 
INTRODUCTION 
 Infectious diseases continue to be a serious threat to public health around the 
world.  Most importantly, the rapid emergence of resistant bacteria makes today’s 
antibiotic’s more and more ineffective, consequently increasing the need for a novel class 
of antibacterial agents.1  The Center for Disease Control and Prevention (CDC) recently 
reported the emergence of several strains of Staphylococcus aureus that are resistant to 
even the most powerful antibiotics of last resort, such as vancomycin.  These data 
emphasize the fact that no drug can prevent a simple staph infection from becoming 
deadly.2  Just 12 years ago, vancomycin failed only ~0.3% of the time in treating 
infections caused by  Enterococcus faecalis, however this number increased 26-fold in 
just four years.3  Various other strains of common bacterial species capable of causing 
fatal illnesses (E. faecalis, Mycobacterium tuberculosis, Escherichia coli O157:H7, and 
Pseudomonas aeruginosa) are already resistant to all existing drugs including 
vancomycin and even to the newest antibiotic linezolid, which was first used in 1990.4,5 
A summary of the commonly used antibiotics, their modes of action, and resistance 
mechanisms is shown in Table 1.6  
In the past, Streptococcus pneumoniae had been susceptible to penicillin, however 
a new drug-resistant strain (DRSP) has recently emerged that is no longer vulnerable to 
penicillin-type antibiotics.4  Recurrently, this type of resistance originates in clinical 
 
 
2
 
 
Table 1. Antibiotics in clinical use and modes of resistance.
Antibiotic 
class 
Example(s) Target Mode(s) of resistance
β-Lactams
Aminoglycosides
Glycopeptides
Tetracyclines
Macrolides
Lincosamides
Streptogramins
Oxazolidinones
Phenicols
Quinolones
Pyrimidines
Sulfonamides 
Rifamycins
Lipopeptides
Cationic peptides 
Penicillins (ampicillin), cephalosporins
(cephamycin), penems (meropenem),
monobactams (aztreonam)
Gentamicin, streptomycin, spectinomycin
Vancomycin, teicoplanin
Minocycline, tigecycline
Erythromycin, azithromicin
Clindamycin
Synercid
Linezolid
Chloramphenicol
Ciprofloxacin
Trimethoprim
Sulfamethoxazole
Rifampin
Daptomycin
Colistin
Peptidoglycan biosynthesis
Translation 
Peptidoglycan biosynthesis 
Translation
Translation
Translation
Translation
Translation
Translation 
DNA replication
C1 metabolism 
C1 metabolism
Transcription
Cell membrane
Cell membrane   
Hydrolysis, efflux, altered target
Phosphorylation, acetylation,
nucleotidylation, efflux, altered target
Reprogramming peptidoglycan biosynthesis
Monooxygenation, efflux, altered target
Hydrolysis, glycosylation, phosphorylation,
efflux, altered target
Nucleotidylation, efflux, altered target
C-O lyase (type B streptogramins),
acetylation (type A streptogramins),
Efflux, altered target
Acetylation, efflux, altered target
Acetylation, efflux, altered target
Efflux, altered target
Efflux, altered target
ADP-ribosylation, efflux, altered target
Altered target
Altered target, efflux
 
3 
environments where pathogenic and commensal bacteria are challenged with high 
concentrations of antibiotics.
7
  Historically it has been shown that within hospital 
settings, resistanat pathogens often emerge within a few years after a new antibiotic is 
introduced (Figure 1).
6
  Pathogens that currently cause the majority of hospital infections  
Figure 1. Antibiotic resistance evolution showing the rapid development of 
resistance for several classes of antibiotics. The bars mark the time from the 
introduction of an antibiotic to the clinic until the first clinical case of resistance to 
that antibiotic was reported.
8,
 
9,
 
10,
 
11
 
 
and urgently require new drug candidates are: Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumonia, Acinetobacter baumanii, Pseudomonas aeruginosa, and 
Enterobacter species (“ESKAPE” pathogens).12   Recently, Gram-negative 
0 5 10 15 20 25 30 35
Penicillin
Methicillin
Ampicillin
Augmentin
Chloramphenicol
Tetracycline
Streptomycin
Kanamycin
Erythromycin
Vancomycin
Nalidixic acid
Norfloxacin
Synercin
Linezolid
Daptomycin
Years from introduction to clinical resistance
Β-lactams
Amphenicols
Tetracyclines
Aminoglycosides
Macrolides
Glycopeptides
Quinolones
Streptogramins
Oxazolidinones
Lipopeptides
Eight years average
4 
Enterobacteriaceae, a bacterium that is resistant to carbapanem due to the New Delhi 
metallo-β-lactamase-1 (NDM-1), made headlines as a major global health problem.  In a 
recent paper published by Kumarasami et al.,
13
 fourtyfour isolates were identified with 
NDM-1 in India, Pakistan, and the UK.  NDM-1 was mostly found among Escherichia 
coli and Klabsiella pneumonia, which were highly resistant to all antibiotics except 
tigecycline and colistin.
13
  
 The newest report from the CDC indicates that the number of estimated annual 
illnesses and deaths caused by antibiotic resistance are 2,049,442 and 23,000, 
respectively.  The CDC has ranked antibiotic-resistant organisms based on seven criteria: 
health impact, economic impact, rate of infection, ten-year projected rate of infection, 
ease of spread, antibiotic availability, and prevention barriers.  Number one in the CDC’s 
most urgent category is Clostridium difficile, which causes 250,000 hospitalizations, at 
least 14,000 deaths and $1 billion in healthcare costs each year.  The other two organisms 
are carbapenem-resistant Enterobacteriaceae (CRE) and drug-resistant Neisseria 
gonorrhoeae.  In March 2013, the CDC called CRE a "nightmare bacteria" being even 
more dangerous than methicillin-resistant Staphylococcus aureus (MRSA).  Among all of 
the bacterial resistance problems, gram-negative pathogens such as Enterobacteriaceae, 
Pseudomonas aeruginosa, and Acinetobacter are particularly dangerous due to becoming 
resistant to nearly all antibiotics.
14
 
Unfortunately, this pattern of resistance will persist as bacteria continue to 
develop ways to survive.  Resistance to antibiotics can be caused by four general 
mechanisms: (a) inactivation or modification of the antibiotic; (b) alteration in the target 
site of the antibiotic that reduces its binding capacity; (c) modification of metabolic 
5 
pathways to circumvent the antibiotic effect; and (d) reduced intracellular antibiotic 
accumulation by decreasing permeability and/or increasing active efflux of the 
antibiotic.
15
  Bacteria can develop resistance to antibiotics by mutating existing genes 
(point mutations, deletions, inversions, insertions, etc.) or by acquiring new genes from 
other strains or species (horizontal gene transfer).
16
 
Despite the critical need for new antibiotics to treat drug-resistant infections the 
number of new antibiotics approved by the Food and Drug Administration (FDA) has 
declined 75 % over the last 24 years with only five new antibiotics approved in the last 
few years and only three novel classes of antibiotics introduced within the last 40 years 
(Figure 2).
17
  In a way, the antibiotic industry has been a victim of its own success.  After 
penicillin and other major antibiotics were discovered it was believed that the battle with 
infectious diseases was conquered.  Life expectancy increased and the number of deaths 
caused by infectious diseases fell tremendously.  Consequently, both grant funding and 
research programs lead by pharmaceutical giants declined significantly.
18
  Many major 
pharmaceutical and biotech companies left the antibiotic research field. For example, 
since 1999, 10 of the 15 largest companies have significantly reduced or eliminated their 
antibiotic research programs.
19
  One major reason why pharmaceutical companies are not 
pursuing antibacterial research is simply due to low profit margins. Antibiotics are short 
course therapies as opposed to billion dollar blockbuster drugs that typically treat chronic 
diseases, such as high cholesterol. Moreover, the increased restrictions on the use of 
antibiotics and more stringent regulatory requirements make antibiotic research even less 
attractive.
20
 In addition, natural compounds such as penicillin have been very successful 
6 
throughout the years and have provided the basic structures from which scientists have 
made many analogues.  Although this rout has been successful and potent compounds  
Figure 2. Number of approved antibiotics between 1935 and 2007. 
 
such as amoxicillin have been discovered, no new classes of antibiotics have been 
discovered and the number of modifications that can be introduced to a compound is 
limited.
20
   
Fortunately, congress together with other organizations finally recognized the 
urgent need to encourage new antibiotic development.  Policymakers are now offering 
pharmaceutical companies patent extensions and tax breaks, in order to revive the interest 
in antibiotic research.  In November 2010, the Infectious Diseases Society of America 
(IDSA) addressed the threat of antimicrobial resistance by insisting U.S. and European 
Union leaders join forces in developing new antibiotics.  To accomplish this goal, IDSA 
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launched a new collaboration titled “10 x `20” initiative.  The goal of this collaboration is 
to create a joint venture that will develop 10 novel antibiotics by 2020.
21
  Governments 
together with other nongovernmental organizations have made significant efforts to 
increase the interest in antibiotic research.  In the US, the federal Interagency Task Force 
on Antimicrobial Resistance updated its “Public Health Action Plan to Combat 
Antimicrobial Resistance” document in 2011.22  On June 12, 2012 Europe’s largest 
public-private partnership between the European Commission and European Federation 
of Pharmaceutical Industries and Associations (EFPIA) held a seminar devoted to the 
clinical development aspects “Combating Antimicrobial Resistance – New Drugs 4 Bad 
Bugs” (ND4BB).  The Innovative Medicines Initiative was set up in 2008 to support 
collaborative research between industrial and academic experts to reduce drug discovery 
bottlenecks and boost pharmaceutical innovation within Europe.
23
  On June 26, 2012, the 
U.S. Senate passed the FDA Safety and Innovation Act (FDASIA) which reauthorizes the 
Prescription Drug User Fee Act (PDUFA) for the fifth time.  The bill was mainly 
designed to speed up reviews of novel drugs for infectious diseases as well as improve 
communication between manufacturers and the FDA to prevent drug shortages.  The 
"Generating Antibiotic Incentives Now" act, which is a part of the PDUFA, was designed 
to provide pharmaceutical and biotechnology companies with incentives to develop new 
antibiotics for the treatment of life-threatening infectious diseases caused by drug 
resistant pathogens.  These pathogens primarily consists of resistant gram positive 
pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin 
resistant Staphylococcus and enterococcus, multi-drug resistant gram negative bacteria, 
including Acinetobacter, Klebsiella, Pseudomonas and E. coli species, multi-drug 
8 
resistant tuberculosis, and Clostridium difficile.
24
  Moreover, it is extremely optimistic to 
see both public and private organizations encouraging research and development by 
combination of various incentives.  
The area of genomics has influenced the discovery of novel antimicrobial agents 
tremendously.  It provided the ability to sequence entire bacterial genomes and identify 
essential genes that upon deletion result in inhibition of cell growth.  The main principle 
lies in the fact that targets should not be shared with a human host and only be present in 
the bacteria that are responsible for the disease.  Libraries of compounds can now be 
screened to find molecules that inhibit the enzymatic function of the target.  Those 
molecules can further be screened for antibacterial activity such as the ability to 
successfully penetrate the cell membrane.
25
  As a result of these advances in genomics, 
the meso-diaminopimelate (mDAP)/lysine biosynthetic pathway was validated as a viable 
source of several potential antibacterial enzyme targets that have yet to be explored 
(Figure 3).
26
  The initial steps in the pathway involve the four step conversion of aspartic 
acid to L-tetrahydrodipicolinate.  This compound can either be directly converted to 
meso-DAP by the dehydrogenase pathway, acetylase pathway or the succinylase 
pathway.  Ultimately, all of these pathways lead to meso-DAP formation.  However, the 
succinylase pathway is the primary biosynthetic pathway in most Gram-negative and 
Gram-positive bacteria for the synthesis of meso-DAP.
27
  The dehydrogenase pathway is 
a high energy transformation and is limited to only few Bacillus species.
27
  The acetylase 
pathway is also limited to only few Bacillus species.
28
 
 
 
9 
Figure 3. Biosynthetic pathways of meso-diaminopimelic acid and lysine in bacteria.
  
The dapE-encoded N-succinyl-L,L diaminopimelic acid desuccinylase (DapE) is 
a member of this meso-diaminopim elate (meso-DAP)/lysine biosynthetic pathway.
27, 20, 
23
  Lysine, which is one of the products of the pathway, is an essential component in the 
production of the peptidoglycan layer of Gram-positive bacterial cell walls.
20
  A second 
product and an immediate precursor of lysine is the amino acid mDAP, which is used in 
the peptidoglycan cell wall of Gram-negative bacteria, providing a link between 
polysaccharide strands.
29,2
  Since there are no similar pathways in mammals, inhibitors of 
DapE are hypothesized to provide selective toxicity against bacteria and show little or no 
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toxicity towards humans.  It has been shown experimentally that deletion of the gene 
encoding for DapE is lethal to Helicobacter pylori and Mycobacterium smegmatis.  Even 
in lysine-supplemented medium H. pylori was unable to grow.  Therefore, DapEs are 
crucial for bacterial cell growth and proliferation.
30, 31
 
DapEs catalyze the hydrolysis of N-succinyl-L,L-diaminopimelic acid (SDAP), 
forming L,L-diaminopimelic acid and succinate (Figure 4).
29   
DapE is an ideal enzyme to  
 
Figure 4. Reaction catalyzed by DapE.
 
study in the mDAP/lysine biosynthetic pathway because it is highly soluble, readily 
available in large amounts, and is capable of being genetically manipulated.  Biochemical 
studies revealed that the DapEs from E. coli and H. influenzae are small (approximately 
42 kDa) dimeric enzymes that require two Zn(II) ions per mole of polypeptide for full 
enzymatic activity.
32
  As-purified, DapE contains only one tightly bound Zn(II) ion and 
exhibits approximately 80% of its total activity.  DapE can be substituted with Co(II) 
providing an enzyme that is twice as active as the native Zn(II) enzyme.
33
  It has also 
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been shown by Broder and Miller that DapE can act as a Mn
2+
-activated Asp-specific 
dipeptidase, by investigating the promiscuity of DapE upon substitution of the active site 
zinc ions with different metals.  Their study indicated that the metal content of DapE’s 
active site regulates its role as an aspartate peptidase, which catalytically cleaves the 
amide bonds of small dipeptide molecules with the general formula of Asp-X, 
particularly Asp-Ser, Asp-Gly, Asp-Lue and Asp-Cys with exception of Asp-Pro.  This is 
possible due to the fact that the second metal binding site has a lower affinity for metal 
ions as compared to the first metal biding site.  Therefore, the authors propose that the 
form of DapE that is active as a peptidase contains Zn
2+
 in the tight binding site and Mn
2+
 
in the low-affinity site.
34
  Homology studies show that alignment of the gene sequences 
of DapE with the aminopeptidase from Aeromonas proteolytica (AAP) and the 
carboxypeptidase from Pseudomonas sp strains-RS-16 (CPG2) indicate that all of the 
amino acids that function as metal ligands are highly conserved.
29,35
 
 
  
Crystal Structure of DapE 
One major limitation in understanding the catalytic mechanism and the design and 
synthesis of inhibitors was the lack of an X-ray crystal structure of DapE enzyme.  The 
only crystal structure of DapE published until 2010 was an apo form of DapE from N. 
meningitidis.
36
  Even though the crystal structure contributed key structural data, the lack 
of active site metal ions made it difficult to determine the spatial arrangement of 
catalytically relevant residues that reside within the active site.  This hurdle was 
overcome when Nocek, Gilner et al.
37
 reported the X-ray crystal structure of both the 
mono- and dinuclear zinc DapE enzymes from H. influenzae and N. menigtididis.  The 
12 
architecture of the active site and the core of the catalytic domain of DapEs could now be 
analyzed in more detail to gain insight on substrate binding and mechanism.  
The X-ray crystal structures of the mono and dinuclear Zn(II)-forms of the DapE 
from H. influenzae were solved at 2.0 and 2.3 Å resolution, respectively.  These 
structures closely resemble the DapE structure from N. meningitidis and as previously 
published the enzyme is organized as a dimer with each monomer divided into two 
domains: a larger catalytic domain, which forms a 3-layer (αβα) sandwich and a smaller 
ferrodoxin-like domain that forms the dimer interface (Figure 5).  The core of the 
catalytic domain, which houses the active site supplies ligands for the zinc ions and 
consists of an eight-stranded twisted β-sheets that are sandwiched between seven α-
helices.  The domains are connected via a small hinge region that allows movements of 
the dimerization domain in reference to the catalytic domain. The shape of the DapE 
homodimer resembles twisted rotary style telephone receiver with the catalytic domain 
located on the outside edge and separated by ~47 Å.  The active site cleft is located in the 
center of the catalytic domain and is constituted by residues from five loops. 
37
 
Obtaining the monozinc form of the DapE enzyme allowed confirmation of 
previously published kinetic and spectroscopic results, which showed that DapE 
maintains activity with only one metal ion in the active site.  It also allowed confirmation 
of the assignment of the first metal binding site.  In the active site of [Zn_(DapE)], Zn1 
resides in a distorted tetrahedral geometry coordinated by the carboxylate oxygens of 
D100 and of E163 as well as one nitrogen atom of H67 (Figure 6).  The second 
coordination site is filled by an oxygen atom provided from a water molecule.   
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Figure 5. Ribbon drawing of dinuclear DapE from H. influenzae.  
 
In [ZnZn(DapE)], the active  site contains two Zn(II) ions at a distance of 3.36 Å apart 
(Figure 7).  Each of the Zn(II) ions adopt a distorted tetrahedral geometry and are 
coordinated by one imidazole group (H67 for Zn1 and H349 for Zn2) and one 
carboxylate group (E163 for Zn1 and E135 for Zn2). Both Zn(II) ions are bridged by an 
additional carboxylate groups of D100 on one side and water/hydroxide on the opposite 
side, forming a (μ‐aquo)(μ‐carboxylato)dizinc(II) core with one terminal carboxylate and 
one histidine residue at each metal site.  These structures confirm previous data 
suggesting that H67 and H349 are active site ligands.
32, 38
  The structure also confirmed 
that the position of glutamate E134 indicates its important role in the catalysis, 
functioning as a general acid/base, previously reported by Davis et al.
38   
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Figure 6. Active site of [Zn_(DapE)] from H. influenzae. 
 
 
Figure 7. Active site of [ZnZn(DapE)] from H. influenzae. 
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Analysis of the molecular surface of DapE together with its X-ray crystal 
structures, revealed a negatively charged cavity that extends along the catalytic domain. 
(Figure 8). It is postulated that the substrate binds in an extended conformation, lining  
Figure 8. Surface rendering of [ZnZn(DapE)] showing the charge distribution and 
depicting the smile‐shaped active site cavity. Blue: positive charge; Red: negative charge. 
 
 
up along the grove with the peptide bond positioned over the active site metals. Substrate 
binding is further stabilized by interactions between substrate carboxylic groups with 
positively charged amino acid side chains.  The potential positive charged residues that 
could possibly play this role are K175, K178, and N345 at one end and R258, R329, and 
K139 at the opposite end (Figure 9).  The side chain of K135 is ~6 Å away from the 
center of the active site, which allows for an interaction of amino group of lysine with the 
carboxylate group of substrate and thus, be involved in recognition and stabilization of 
substrate at the active site.  On the opposite side, the carboxyl group of L,L‐ SDAP could 
be stabilized by an interaction with R258 and R329. T325, which is centrally positioned  
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Figure 9. Side chains potentially involved in binding and substrate stabilization.  
 
 
on a loop overhanging the active site, is also in hydrogen bond distance (3.11 Å) of the 
carboxyl group of the L,L‐ SDAP moiety. 
The architecture of the active site and the core of the catalytic domain of HiDapE 
are strikingly similar to AAP and CPG2, even though they catalyze markedly different 
hydrolytic reactions.
39,40
  These structures provide an important starting point for 
mechanistic studies as well as the design of novel inhibitors for DapE enzymes.    
Proposed Mechanism of DapE 
Based on the X-ray crystal structure, previously reported kinetic and 
spectroscopic studies of DapE and the recently published mechanisms of AAP
41,
 
41b
 a 
refined catalytic mechanism for DapE was proposed (Figure 10).
37
  After recognition of 
the L,L-SDAP the peptide carbonyl oxygen of L,L-SDAP coordinates to Zn1, expanding 
17 
its coordination number from four to five and activating towards nucleophilic attack.  
Once the zinc-bound hydroxide is formed, it can attack the activated carbonyl carbon of 
the substrate, forming an η-1-μ-transition-state complex.33  E134 provides a proton to the 
penultimate amino nitrogen of SDAP, which facilitates product release.  Once the 
products are released, a water molecule bridging the two metal ions is replaced.  In the 
absence of a second metal ion, H349 is in position to assist in orienting the substrate 
properly in the active site through the formation of a hydrogen bond with a carboxylate 
side chain of the substrate, thereby stabilizing the transition-state intermediate.  In the 
presence of a dinuclear site the second metal ion likely coordinates either the peptide 
carbonyl oxygen in a bridging fashion or a carboxylate side chain of the substrate. 
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Figure 10. Proposed mechanism of DapE (a) monozinc DapE and (b) dizinc DapE. 
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Potential Inhibitors of DapE 
Several compounds containing zinc-binding groups (ZBG’s) including thiols, 
carboxylic acids, boronic acids, phosphonates and hydroxamates have been screened 
delivering a number of micromolar inhibitors of DapE from H. influenzae.  Thus far, the 
most potent inhibitors include L‐captopril (IC50 = 3.3 μM, Ki = 1.8 μM), L‐penicillamine 
(IC50 = 13.7 μM , Ki = 4.6 μM), 2‐thiopheneboronic acid (TPhB) (IC50 = 92 μM, Ki = 67 
μM) and phenyl boronic acid (PhB) (IC50 = 107 μM, Ki = 56.9 μM).
42 
  Particularly 
interesting is the fact that DapE is stereoselective with respect to recognition of 
inhibitors.  D‐penicillamine and D‐captopril are weaker inhibitors than the corresponding 
L‐isoform. Since crystallization attempts for DapE from H. influenzae in the presence of 
L‐captopril, L‐penicillamine, 2‐thiopheneboronic acid or phenyl boronic acid have been 
unsuccessful, an orthologous crystallization approach has been undertaken as 
homologous proteins have different propensities for crystallization.  While the amino-
acid sequences of homologues indicate a similar fold, there may be subtle differences so 
crystallization can occur under alternative conditions providing inhibited structures.
43
  By 
pursuing this goal the chances of obtaining structures with inhibitors bound to the active 
site will increase.  The other advantage of this approach is that a broader spectrum of 
DapE targets can be analyzed, which will provide additional structural insight to 
understand the mechanism of the DapE enzyme family.  Ultimately we were able solve 
crystal structures of mono and di-zinc forms of DapE from N. meningitidis utilizing this 
approach, which will provide insight for the rational design of highly‐selective inhibitors 
of DapE. 
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Conclusion 
The importance of this project is accentuated by the increasing rate of antibiotic 
resistant bacteria, which has escalade to become a worldwide crisis.  The research 
presented in this dissertation provides insight into substrate-binding as well as the 
mechanism of DapE, which has been identified as a potential antimicrobial target.  
Moreover, the information elucidated from the experimental data shine light onto the 
binding of inhibitors and provides important information required for the design of 
inhibitors of DapE enzymes.  Rational design of inhibitors relies on understanding the 
active site structure and catalytic mechanism.  Therefore, the DapE enzymes from H. 
influenzae and N. meningitidis were characterized biochemically and crystallographically.  
In addition, residues situated within the active site were mutated and characterized via 
kinetic and crystallographic methods to gain insight into substrate binding.  In order to 
examine the role of the catalytic domain of DapE truncated enzymes from Vibrio cholera 
and H. influenzae were engineered by deleting their dimerization domains.  Moreover, 
inhibition of DapE with L-captopril was investigated using several spectroscopic as well 
as crystallographic techniques, which produced the first inhibited structure of DapE.  
More importantly, the research has identified a viable assay for High Throughput 
Screening of Inhibitors, which allows for testing of a large number of inhibitors in a short 
period of time.  This approach has allowed five new potential inhibitor of DapE to be 
identified, that can be used as synthons for future design of potent inhibitors.  This work 
has provided information that could benefit the healthcare and the general wellbeing of 
society given that multidrug resistant bacteria pose a serious and increasing threat to 
human health.   
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CHAPTER TWO 
THE ROLE OF THE DIMERIZATION DOMAIN AND THE ACTIVE SITE 
LOOP IN DAPE ENZYMES 
Introduction  
 
Emerging antibiotic resistance has been recognized as a world-wide health issue 
since the introduction of penicillin more than 80 years ago.4, 44  Most importantly, the 
rapid emergence of resistant bacteria makes today’s antibiotics more and more 
ineffective, consequently increasing the need for a novel class of antibacterial agents.45  
Currently available antibiotics target only a limited number of microbial pathways and 
employ two major strategies: (i) inhibition of cell wall remodeling and (ii) inhibition of 
protein synthesis.46  As a result, only two new classes of antibacterial drugs have reached 
the market since 1962.47, 48, 49  The Center for Disease Control and Prevention (CDC) 
recently reported the emergence of several strains of Staphylococcus aureus that are 
resistant to even the most powerful antibiotic of last resort, vancomycin.  These cases 
emphasize the fact that no drug can prevent a simple staph infection from becoming 
deadly.50 According to the Infectious Diseases Society of America (IDSA), a minimum of 
ten new systemic antibacterial drugs need to enter the market by the year 2020 in order to 
maintain proper control of infectious diseases.  Therefore development of new classes of 
inhibitors that target essential metabolic pathways and unique enzymes is critical in order 
to maintain control of infectious diseases.21, 51 
22 
 
The lysine biosynthetic pathway offers several enzymes that could serve as 
potential drug targets. 
52,
 
53, 54
  Two products of this pathway, lysine and meso-
diaminopimelate (mDAP), are essential for protein and peptidoglycan cell wall synthesis 
in Gram-negative and most Gram-positive bacteria. Many bacteria, plants and algae 
synthesize lysine and meso-diaminopimelic acid (mDAP) from succinic acid.
27-28, 53
  In 
contrast, lysine is not synthesized in humans but it is an essential amino acid, therefore it 
must be ingested.  It has been shown that deletion of the dapE gene in the mDAP/lysine 
biosynthetic pathway that encodes the N-succinyl-L,L-diaminopimelic acid desuccinylase 
(DapE) is lethal in Helicobacter pylori and Mycobacterium smegmatis.
55
  DapE 
hydrolyzes N-succinyl-L,L-diaminopimelic acid to L,L-diaminopimelic acid and 
succinate.
53
  DapE is a part of a biosynthetic pathway that is the major source of lysine in 
bacteria, and is essential for cell growth and proliferation.  Since there are no similar 
biosynthetic pathways in mammals, inhibitors that target DapEs are hypothesized to 
exhibit selective toxicity against bacteria and have little or no effect on humans.
27
  DapE 
coding genes have been identified in all pathogenic Gram-negative bacteria, and the 
enzyme has been purified and characterized from several sources.
55a, 55b,
 
56, 57,
 
58, 59
  Of 
particular interest are DapEs from the “ESKAPE” pathogens, which are responsible for 
an increasing number of the antibiotic resistant nosocomial infections in the United 
States.
60
 Alignment of the DapE gene from Haemophilus influenzae (HiDapE) with the 
gene sequences of DapEs from “ESKAPE” pathogens reveals at least 49% identity.61   
All the DapE enzymes characterized to date belong to the M20 family of 
dinuclear Zn(II)-dependent metalloproteases.  Structural studies of M20 metalloproteases 
23 
 
showed that these enzymes exist as dimers comprised of catalytic and dimerization 
domains or monomers having a single catalytic domain.
62
  Structural studies on HiDapE 
revealed that the enzyme belongs to the former group composed of a larger thioredoxin-
like 3-layer (αβα) sandwich domain that carries out catalysis and a smaller ferrodoxin-
like domain providing the dimer interface. The core of the catalytic domain consists of an 
eight-stranded twisted β-sheet that is sandwiched between seven α-helices and houses the 
active site.  The active site is constituted by residues from five loops, contains two zinc 
ions, and is exposed to the solvent.
63
   
The architecture of the active site of HiDapE and the core of the catalytic domain 
are strikingly similar to the aminopeptidase from Aeromonas proteolytica (AAP) and the 
carboxypeptidase from Pseudomonas sp strain-RS-16 (CPG2) 
64
, even though they 
catalyze markedly different hydrolytic reactions.  One explanation for this similarity is 
the highly flexible design of their active sites, which are constructed by five loops.  This 
design preserves the dinuclear catalytic core and at the same time allows for evolution of 
specificity for a new substrate without the need for major modifications to the overall 
structure.  The flexibility of the active site is especially relevant from the perspective of 
understanding substrate recognition and binding which is directly related to inhibitor 
design.  In order to examine the role of the catalytic domain of DapE enzymes and the 
role of the active site loops, we have engineered the HiDapE and the DapE from Vibrio 
cholerae (VcDapE) by deleting their dimerization domains.  This truncation leads to 
protein constructs that have only the catalytic domain, are monomeric in solution, and 
closely resemble AAP.  Kinetic characterization of the truncated DapEs (VcDapE
T
 and 
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HiDapE
T
) shows that the activity of catalytic domain is not detectable under standard 
assay conditions.  X-ray crystallographic data and molecular dynamic simulations along 
with site-directed mutagenesis studies provide insight into the role of the dimerization 
domain and emphasize the importance of the active site loops in catalysis. 
Materials and Methods 
Gene cloning and protein expression—The coding genes of full-length VcDapE 
and HiDapE that were cloned in vector pMCSG7 were amplified by PCR from V. 
cholerae O1 biovar El Tor str. N16961 (ATCC) and from H. influenzae strain (ATCC) 
respectively with KOD DNA polymerase using conditions and reagents according to the 
standard protocol described previously.
65
  The truncated version of HiDapE
T
 (residues 
181-294 deleted) and VcDapE
T
 (residues 181-295 deleted) were designed based on the 
full-length HiDapE structure and were cloned using the same procedure.  These deletion 
proteins were reengineered in such a way that the C-terminal domain was truncated at the 
connector region between the dimerization and the catalytic domains and replaced with a 
GG linker.  The deletion of the region coding for the dimerization domain was achieved 
via PCR of pMCSG7-VcDapE and pMCSG7-HiDapE according to the previously 
described protocol.
66
  The following primers were used: VcDapE
T
 181-295; 
5’TGGCGGTGGCTTCCTGACCGATACGGGCGA3’and 
5’GGAAGCCACCGCCACGACGGCCATTTTTCACC3’, HiDapET 181-
294;5’CGGCGGTGGCTTTTTAACAAAACCAGGTAAATTATTAGATTCGATAACC
3’ and 5’AAAAAGCCACC GCCGCGGCGACCATTTTTGAC3’. This process 
generated expression clones of fusion proteins that have the N-terminal His6-tag followed 
25 
 
by a TEV protease recognition site (ENLYFQ↓S) followed by the DapE catalytic 
domain.  All proteins were expressed in an E. coli BL21(DE3)-derivative that harbors the 
pMAGIC plasmid encoding one rare E. coli Arg tRNA (covering codons AGG/AGA).  
The transformed BL21(DE3) cells were grown at 37 °C in LB medium and protein 
expression was induced with 1 mM isopropyl-β-d-thiogalactoside (IPTG).  The cells were 
then incubated and shaken vigorously at 18 °C overnight.  The harvested cells were re-
suspended in lysis buffer (500 mM NaCl, 5% (v/v) glycerol, 50 mM HEPES, pH 8.0, 10 
mM imidazole, 10 mM 2-mercaptoethanol) and stored at −80 °C. 
Purification of VcDapE, VcDapE
T
 and HiDapE
T—The VcDapE, VcDapET and 
HiDapE
T
 proteins were purified according to the standard Ni-NTA affinity 
chromatography protocol described previously.
65
  The 6-His tag was removed by treating 
each enzyme with TEV protease for 16 h at 4 °C in 50 mM HEPES, pH 7.5.  Cleaved 
protein was separated from TEV using Ni-NTA affinity chromatography.  After Ni-NTA 
column chromatography, VcDapE
T
 and HiDapE
T
 were further purified by size-exclusion 
chromatography on a HiLoad 16/600 Superdex 200 Prep Grade (GE Healthcare) using 
standard crystallization buffer (250 mM NaCl, 20 mM HEPES pH 7.5, and 1 mM TCEP) 
and concentrated to 25 mg/ml.  The full-length VcDapE protein was purified according to 
the same procedure however the size-exclusion chromatography step revealed formation 
of “soluble aggregates”.  Therefore, the buffer conditions were altered such that the salt 
concentration was increased to 800 mM NaCl and glycerol (10%) was added, allowing for 
purification of a small quantity of soluble protein.  
26 
 
Determination of Molecular Weight of VcDapE, VcDapE
T
 and HiDapE
T
 —The 
molecular weight (MW) of HiDapE,
 
HiDapE
T
  and VcDapE
T
  proteins in solution  at 
concentration of 5 mg/ml was evaluated by size-exclusion chromatography (SEC) on a 
HiLoad 16/600 Superdex 200 Prep Grade column (GE Healthcare) in the crystallization 
buffer. The column was calibrated with aprotinin (6.5 kDa), ribonuclease A (13.7 kDa), 
carbonic anhydrase (29 kDa), ovalbumin (43 kDa), conalbumin (75 kDa), aldolase (158 
kDa), ferritin (440 kDa), and thyroglobulin (669 kDa) as standards. The calibration curve 
of Kav versus log MW was prepared by using the equation Kav=Ve–Vo/Vt–Vo, where 
Ve=elution volume for the protein, Vo = column void volume, andVt=total bed volume 
(Figure 11).  
Figure 11. Analysis of the oligomeric state by size exclusion chromatograpy. 
Chromatogram showing elution of three DapE proteins  (WT-HiDapE (blue), HiDapE
T 
(red), VcDapE
T
(green)) from the calibrated column.  The inset shows the calibration 
curve obtained by plotting Kav versus logMW forthe following standard proteins: 
Aprotinin (6.5 kDa, I), ribonuclease A (13.7 kDa, II), carbonic anhydrase (29 kDa, III) 
ovalbumin (43 kDa, IV), conalbumin (75 kDa, V), aldolase (158 kDa, VI), ferritin (440 
kDa, VII), and thyroglobulin (669 kDa, VIII). 
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 Kinetic characterization of VcDapE, VcDapE
T
, and HiDapE
T—Recombinant WT-
VcDapE, VcDapE
T
, and HiDapE
T
 were characterized biochemically by monitoring amide 
bond cleavage of L,L-SDAP at 225 nm ( = 698 M-1 cm-1).  The assay was performed in 
triplicate in 50 mM phosphate buffer, pH 7.5, in the presence of two equivalents of Zn(II).  
Enzyme activities were expressed as units/mg where one unit is defined as the amount of 
enzyme that releases 1 µmol of L,L-SDAP at 25 °C in 1 min.  Km and kcat values were 
obtained by fitting initial rates data to the Michaelis-Menten equation using Origin 
software.
59, 67
  Catalytic activities were determined with an error of ± 10%. 
Protein crystallization—The sitting-drop vapor-diffusion method was used to 
obtain crystals of VcDapE
T 
and HiDapE
T
 at 16 °C using a Mosquito liquid handling robot 
with 96 well plates.  Crystals of both the apo- and dinuclear Zn(II)-loaded forms of 
VcDapE
T
 were obtained using 400 nl of a precipitant solution (20% (v/v) 1,4-butanediol, 
0.1 M sodium acetate pH 4.5) and 400 nl of a 19 mg/ml solution of VcDapE
T
 in 
crystallization buffer within 14 days.   In order to grow the crystals of dinuclear Zn(II)-
loaded forms of VcDapE
T
 1mM ZnCl2 solution was added to the protein solution.  
Crystals of HiDapE
T
 were obtained using 400 nl of a precipitant solution (0.2 M 
ammonium acetate, 0.1 M BIS-TRIS pH 5.5, 25% (w/v) polyethylene glycol 3350) and 
400 nl of a 15 mg/ml solution of HiDapE
T
 within two weeks.  The asymmetric unit 
contains two monomeric molecules of the HiDapE
T
.  For cryoprotection, all crystals were 
transferred to, the mother liquid containing 25% mixture of glycerol and ethylene glycol. 
Data collection and structure determination—Prior to data collection, the X-ray 
florescence spectrum was recorded for VcDapE
T
, HiDapE
T
 and apo-VcDapE
T
 crystals, 
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which identified the presence of Zn ions in the protein crystals of VcDapE
T
 and HiDapE
T
.  
Data collection was carried out on the 19-ID beam line of the Structural Biology Center 
at the Advanced Photon Source according to procedures described previously.
63
  Data 
were collected at a wavelength of 0.98 Å from the single crystals and were processed 
using HKL3000. Crystallographic parameters are summarized in Table 2.  Initially data 
for both VcDapE
T
 were processed, scaled and structures were refined in the space group 
P3212.  Even though models refined to low R-factor (Rcryst/Rfree= ~16/18%), the spurious 
density features were observed in the electron density maps. Re-examination of the data 
and twinning test performed using Xtriage in Phenix 
68
 indicated a perfect twinning with 
the twinning operator parallel to two-fold axis making it pseudo P3212. Therefore data 
were rescaled in the space group P32.  The structures of VcDapE
T
 and HiDapE
T
 were 
determined by molecular replacement using the catalytic domain of HiDapE (PDB ID 
3IC1) as a search model.
63
  Molecular replacement searches were completed using 
MOLREP of the CCP4 suite.
69
 The initial models were rebuilt manually and refined 
using programs  REFMAC 5.5 
70
 and Phenix.
68
 The final models were refined against all 
reflections except for 5% randomly selected reflections, which were used for 
monitoring Rfree.  The final rounds of refinement were carried out using TLS refinement 
with 5 TLS groups.  The final refinement statistics for all structures are presented in 
Table 2.  Analysis and validation of the structures were performed with the aid of 
MOLPROBITY and COOT validation tools.  Figures were prepared using program 
Pymol. 
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Table 2. Data and Refinement Statistics for VcDapE
T
-apo, VcDapE
T
-ZnZn and HiDapE
T
-
ZnZn. 
Data collection statistics VcDapE
T
-apo VcDapE
T
-ZnZn HiDapE
T
-ZnZn 
Space group P32 P32 P21 
Unit cell (Å) a = 49.6, 
b =49.6,  
 c = 232.6 
a = 49.9, 
b =49.9,  
 c = 231.8 
a = 61.7, 
b = 44.7, 
c = 92.5, 
o 
Resolution (Å) 37.6-1.65 40-1.65 30-1.84 
Wavelength (Å) 0.98 Å 0.98 0.98 
Number of observed reflections 523779 299329 99336 
Number of unique reflections 77006 70716 42453 
Redundancy 
b
 6.8 (3.8) 4.2(1.8) 2.3(2.2) 
Rmerge
a,b
 (%) 
Rrim
 a,b
 (%) 
Rpim
 a,b
 (%) 
5.9 (50.1) 
6.4 (56.7) 
2.4 (25.8) 
5.1  (26.0) 
5.8  (35.5) 
2.6 (23.1) 
9.2 (55.7) 
10.5(82.6) 
6.5(51.0) 
Completeness
b
 (%) 99.6 (93.8) 91.3 (49.2) 96.5 (97.8) 
I/σ 40 (2.3) 23.2 (2.1) 9.5 (2.1) 
Phasing 
phasing method MR MR MR 
Refinement statistics 
Rcryst (%) 13.81 14.32 19.7 
Rfree (%) 17.13 16.59 24.9 
protein residues 532 513 505 
zinc ion/acetate/butanediol/ 
glycerol/ethanediol/ 
-/1/6/2/4 2/-/6/3/3 4/-/-/-/- 
solvent 541 541 284 
Rmsd from target values 
bond lengths (Å) 0.020 0.020 0.021 
bond angles (deg) 2.11 1.43 2.03 
Average B factors (Å
2
) 
protein  14.78 14.77 27.7 
Zn - 13.93 26.1 
H2O 28.10 24.19 38.7 
PDB ID 4ONW 4OP4 4H2K 
Ramachandran (%)
c   
M.F./A.A. 97.5/2.5 97.3/2.7 96.8/3.0 
a
 Rmerge = ΣhklΣi|Ii(hkl) − Ihkl|/ΣhklΣiIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, and〈Ihkl〉is the 
weighted average intensity for all observations i of reflection hkl. 
  Rrim = Σhkl(N/(N − 1)
1/2)Σi|Ii(hkl) −   h   l |/ΣhklΣiIi(hkl), and Rpim = Σhkl(1/(N − 1)
1/2)Σi|Ii(hkl) −   h   l |/ΣhklΣiIi(hkl). 
b 
Numbers in parentheses are values for the highest-resolution bin. 
c
As defined by MOLPROBITY (M.F. –the most favored/ A.A additionally allowed) 
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Protein Data Bank accession code—The atomic coordinates and structure factor 
file for the structure of the catalytic domain of apo-VcDapE
T
, ZnZn-VcDapE
T
 and ZnZn-
HiDapE
T
 have been deposited in the RCSB Protein Bank with accession code 4ONW, 
4OP4 and 4H2K, respectively. 
Molecular modeling and dynamics simulations—The structure of the catalytic 
domain of VcDapE
T
 is well ordered and excellent electron density is observed for protein 
main-chain, side-chains, metal, phosphate ions, and water molecules.  Using the VMD 
molecular graphics program 
71
, the protein model with its hydrogen atoms was created 
and placed in a water-box containing 7826 TIP3 water molecules 
72
, 13 sodium, and 2 
chloride ions to neutralize the charge and provide counter ions.  The charges on the 
histidine residues were determined by inspection of their local environments.  The energy 
of this initial structure was minimized with 3,000 steps of conjugated gradient 
minimization using the CHARMM27 force field 
73
 and the NAMD molecular dynamics 
(MD) program.
74
  The structure was relaxed by gradually heating it from 10 to 310 K in 
steps of 10 K with 1,000 steps of molecular dynamics at each temperature.  Periodic 
boundary conditions were used.  The cutoffs for non-bonding (van der Waals and 
electrostatic) interactions were 12 Å.  The switch distance was 10 and 1.0 Å using a 1–4 
scaling factor.  The time step was 2 fs.  These conditions were used for all of the 
molecular dynamics simulations.  After 10,000 steps of pressure and temperature 
equilibration using a Langevin piston, the system was subjected to 30,000 steps of 
molecular dynamics.  This process constitutes equilibration of the structure.  The 
structures for HiDapE
T
 and HiDapE were also equilibrated in the same manner.  Since 
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these X-ray structure models had a few loops missing due to the poor electron density 
maps, the missing regions were modeled using the modeling tools found in Swiss PDB 
Viewer.
75
 The complete VcDapE structure was produced through homology modeling, 
using HiDapE as a template through the automated mode of the Swiss Model service.
76
  
The two chains of VcDapE were produced separately from each other, combined using 
VMD, and equilibrated in the manner previously described.  The X-ray structure for AAP 
(PDB ID 1RTQ) 
64b
 was used as a standard for comparison as AAP and dinuclear Zn(II)-
loaded VcDapE
T
 and HiDapE
T
 are characterized by similar active sites and sequence 
lengths.  For each of these five structures, 5 ns of simulation data were accumulated.  The 
rmsd per residue values were calculated for MD production runs of the four structures 
using the VMD molecular graphics program.
71
  These calculations were used to 
determine structural changes between each of the five structures.  MOLMOLplots 
77
 were 
also generated for each structure to give a visual depiction of the structural changes, 
especially for areas of large movement.  For these diagrams 171 equally spaced snapshots 
over a 5 ns simulation were used for each of the five proteins.  Three of the simulations 
(ZnZn(VcDapE
T
), HiDapE
T
 and HiDapE) were run for 10 ns, but there were no 
significant differences in the flexibilities of these when the second 5 ns were compared 
with the first 5 ns.  All of the MOLMOL plots (Fig 13 and 14) used only the first 5 ns of 
data so that they are directly comparable. 
Loop V Site Directed Mutagenesis—The site-directed mutants T325A, T325S and 
T325C of WT-HiDapE were prepared using the Quick Change Site-Directed Mutagenesis 
Kit (Stratagene) following the procedure outlined by Stratagene using the following 
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primers, T325A: 5’-ACAGGTGGCGGCGCGTCAGACGGTC-3’, 5’-
GACCGTCTGACGCGCCGCCACCTGT-3’, T325S: 5’-
ACAGGTGGCGGCTCGTCAGACGGTC-3’, 5’-
GACCGTCTGACGAGCCGCCACCTGT-3’, T325C: 5’- 
GCTGAAACAGGTGGCGGCTGCTCAGACGGTCGTTTTATT-3’, 5’-
AATAAAACGACCGTCTGAGCAGCCGCCACCTGTTTCAGC-3’.  Polymerase Chain 
Reaction (PCR) was performed using 70 ng of a dsDNA template.  PCR was performed 
at 95 °C for 30 seconds followed by 16 cycles of (95 °C for 30 seconds, 55 °C for 1 
minute, 68 °C for 5 minutes) and final extension at 68 °C for 6 minutes.  Reaction 
products were transformed into BL21(DE3)/magic E. coli competent cells (Invitrogen) 
and grown on Luria-Bertani agarose plates containing ampicillin (100 µg mL
-1
) and 
kanamycin (25 µg mL
-1
).  A single colony of each mutant was grown in 5 mL Luria-
Bertani medium containing ampicillin (100 µg mL
-1
) and kanamycin (25 µg mL
-1
).  
Plasmids were isolated using the QIAprep-Spin Miniprep Kit (QIAGEN).  The plasmid 
DNA was sent to the DNA sequencing facility (University of Chicago Cancer Research 
Center DNA Sequencing Facility, Chicago IL) to confirm the mutations.  Glycerol stocks 
were prepared and stored at -80 °C until further needed.  Purification of HiDapE T325A, 
T325C and T325S mutant enzymes and kinetic characterization was conducted as 
described above.   
Circular Dichroism (CD) Spectroscopy— The secondary structure of WT DapE 
and T325 mutants were measured using Olis DSM 20 circular dichrometer.  Data was 
collected at room temperature with constant nitrogen flow every 1 nm, in the wavelength 
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range of 190 - 260 nm. All samples were measured in a cylindrical quartz cuvette with a 
1 mm pathlength in 10 mM phosphate buffer pH 7.0. Three repetitive scans were 
averaged, smoothed and background-subtracted for each measurement. Millidegree 
values obtained were converted to molar ellipticity (deg·cm
2
·dmol
-1
) by using the 
equation: Molar ellipticity = moM/10×L×C, where mo is millidegrees, M is molecular 
weight (g/mol), L is path length of cuvette (cm) and C is concentration (g/L). CD data 
from 190 to 260 nm were also analyzed to estimate the secondary structure composition 
of Wild type and the mutants using the CDSSTR program in Dichroweb.
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Results 
Kinetic characterization of wild type and truncated DapE—Kinetic data were 
obtained for recombinant VcDapE, HiDapE, VcDapE
T
, and HiDapE
T
 by monitoring 
amide bond cleavage of L,L-SDAP at 225 nm.  The kcat value obtained for WT-VcDapE 
was 80 ± 10 s
-1 
with a corresponding Km value of 1.2 ± 0.2 mM while the kcat value 
obtained for HiDapE was 114 ± 10 s
-1
 with a Km value of 0.8 ± 0.1 mM, which is in good 
agreement with previous studies.
67b
 Surprisingly, no detectable activity was observed for 
HiDapE
T
 or VcDapE
T
 under the standard assay conditions.   
Structure of the catalytic domain of HiDapE
T—Deletion of the dimerization 
domain led to a monomeric structure for HiDapE
T
. The monomeric nature of HiDapE
T
 in 
solution was corroborated by size exclusion chromatography (SEC) The SEC analysis 
confirmed a weight (MW) of 28.4 kDa (the theoretical mass of a monomer is 28.9 kDa, 
while the wild-type dimer’s theoretical mass is 82.6  Da) (Figure 11).  The structure of 
HiDapE
T
 was determined and refined at 1.84 Å resolution and the final model shows two 
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independent monomers in the asymmetric unit.  The structure of the catalytic domain is 
virtually identical to the catalytic domain of full-length HiDapE (PDB ID 3IC1) (Figure 
12A, B, & C).
63
  Both structures overlay closely with rmsd for Cα atoms of 0.65 Å over 
254 residues.  Two zinc atoms were found in the active site and reside in the same 
position as in dimeric structure of WT-HiDapE separated by 3.40 Å.  Superimposition of 
the active site regions shows nearly identical conformations of main chain and side 
chains with rmsd as low as 0.15 Å for the metal ions and side chains of residues involved 
in their coordination (Figure 12C).  Therefore the structure of the catalytic core of the 
enzyme is extremely well preserved.  Larger differences within the active site area are 
observed in two regions containing solvent exposed loops.  Region I (residues 176-187) 
has been engineered to replace what was originally the connector/hinge region formed by 
two loops linking the catalytic domain with the dimerizaton domain (Figure 12C, Region 
I).  This region is highly flexible and is disordered in the crystal structure of HiDapE
T
  
(with no electron density observed for residues 182-187).  Region II (residues 209-224), 
which corresponds to a loop overhanging the active site metal ions (loop V, vide infra) 
adopts a different conformation in comparison to that observed in the HiDapE structure 
(rmsd of 1.5 Å between the structures).  Two residues within loop V (Gly21 and Gly212) 
are disordered in the structure of HiDapE
T
 (Figure 12C). 
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Figure 12.  X-ray Crystal Structures of WT-HiDapE and HiDapE
T
. (A) Dimer 
architecture based on the structure of WT-HiDapE.  (B) Close-up view of the catalytic 
domain of WT-HiDapE.  Ribbon diagram showing the active site formed by six loops 
(LI-LVI); five of them coordinate the Zn ions (LI-IV & VI).  (C) Superimposition of the 
structure of WT-HiDapE (black) over HiDapE
T
 (magenta).  Active site Zn(II) ions are 
shown as black and magenta  spheres for WT-HiDapE and HiDapE
T
, respectively.  
Regions where differences are most prominent are labeled Region I (yellow) and Region 
II (orange).  Yellow and magenta circles highlight two disordered loop regions in the 
HiDapE
T
 structure. The red dots marked disordered loop that contains conserved His 
residue.  
 
 
 
 
 
 
 
36 
 
Structure of the catalytic domain of VcDapE
T—The monomeric state of VcDapET 
was confirmed by SEC (the estimated MW of 28.7 kDa). Two VcDapE
T
 structures were 
determined, the apo- and the dinuclear Zn(II)-loaded form. The final models for both 
apo- and Zn(II)-loaded VcDapE
T
 included two molecules of the catalytic domain in the 
asymmetric unit.  The two V. cholerae structures are virtually identical and superimpose 
with the average rmsd of 0.25 Å for 265 equivalent C atoms suggesting that binding of 
Zn(II) does not induce any major structural changes (Figure 13A).  The structures of the 
catalytic domains of both apo- and Zn(II)-loaded VcDapE
T
 closely resemble that of the 
catalytic domain of active WT-HiDapE (PDB ID 3IC1). Superimposition of the Zn(II)-
loaded VcDapE
T
 structure and Zn(II)-loaded HiDapE
T
 shows that they also overlay 
closely with (the average rmsd of 0.81 Å for 248 equivalent C atoms, Z-score 17, 
sequence similarity 59%) (Figure 3B).  Likewise, the structure of Zn(II)-loaded VcDapE
T
 
is almost identical to that of the catalytic domain of the full-length HiDapE with rmsd of 
1.15 Å.  The similarity between these structures is especially apparent within the active 
site region of Zn(II)-loaded VcDapE
T 
as the active site structure differs by only ~0.45 Å 
rmsd with the active site of HiDapE
T
 and ~0.4 Å with the WT-HiDapE (Figure 13A and 
B).  Similarly to HiDapE
T
, the most flexible regions of the protein are Region I and 
Region II.  Region I corresponds to the engineered loop (the connector) where the deleted 
dimerization domain is replaced with two glycines.   Region II (residues 210-224) forms 
a loop overhanging the active site metal ions, which includes residues 211-213 that form 
part of loop V (vide infra) (Figure 13B). 
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The active sites of HiDapE
T
 and VcDapE
T—The sequence identity of HiDapE and 
VcDapE is high (59%), and the residues comprising the active site are fully conserved.  
The active site of DapE is located in the center of the catalytic domain above the centrally 
located parallel strands of the -sheet and is formed by six loops [loop I (H. influenzae 
notation, residues 68-75), loop II (residues 95-102), loop III (residues 132-141), loop IV 
(residues 162-174), loop V (residues 322-328 in HiDapE) and loop VI (residues 341-355)] 
(Figure 12B).  With the exception of loop V that does not interact with the zinc ions, the 
remaining loops contribute the conserved residues that coordinate the metal ions (Figures 
12B, 12C & 13B).  Interestingly, loops I-IV and VI are in virtually identical orientations 
in both VcDapE
T 
and HiDapE
T
 and overlay very well with the corresponding loops in the 
WT-HiDapE.  A change is observed in loop V which in VcDapE
T
 adopts a confirmation 
that is significantly different from the one observed for WT-HiDapE (Figures 12A & 13B) 
(in HiDapE
T
 this loop is disordered).  The active site of Zn(II)-loaded VcDapE
T
 contains a 
(μ-oxygen)(μ-carboxylato)dizinc(II) core with one terminal carboxylate and one histidine 
residue at each metal site ([ZnZn(VcDapE
T
)]), that is identical to the active site observed 
for WT-HiDapE.
63
 The main difference between the active sites in the two Zn(II)-loaded 
H. influenzae structures (WT-HiDapE and HiDapE
T
) and [ZnZn(VcDapE
T
)] is the 
presence of additional electron density in chain A, which is overlapping with the bridging 
water/hydroxide molecule observed in chain B and WT-HiDapE.  The 2Fo-Fc and Fo-Fc 
electron density maps were quite clear and indicate that a small molecule (most likely 
ethylene glycol or a partially disordered glycerol molecule) (Figure 3C) displaces the 
bridging water/hydroxide molecule in the [ZnZn(HiDapE)] and [ZnZn(HiDapE
T
)] 
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structures.  Both of these compounds were present in the cryoprotectant solution.  Based 
on the best fit, an ethylene glycol molecule was modeled in the active site resulting in 
distorted tetrahedral coordination geometry for Zn1, which is bound by the carboxylate 
Figure 13. X-ray Crystal Structures of VcDapE
T
. (A) Superimposition of apo-VcDapE
T
 
(blue) over [ZnZn(VcDapE
T
)] (cyan), showing the identical nature of the catalytic 
domains.  Zinc atoms for VcDapE
T
 are shown as black spheres.  (B) Comparison of 
[ZnZn(VcDapE
T
)] (cyan) and [ZnZn(HiDapE
T
)] (magenta).  Regions I (yellow) and II 
(orange) identify the areas where the most significant differences between the two 
structures exist.  Six loops (LI-LVI) forming the active site are labeled.  Zinc atoms for 
VcDapE
T
 are shown as black spheres while the residues coordinating the metal ions are 
shown as lines.  (C) Close-up view of the active site environment of the 
[ZnZn(VcDapE
T
)] with the 2Fo−Fc electron density map (with the Zn ions and ethylene 
glycol molecules omitted from the calculation).  (D) Close-up view of residues from 
loops I-IV and VI interacting with the Zn(II) ions in the structure of [ZnZn(VcDapE
T
)]. 
(E) The 2Fo-Fc (blue, 1 σ) and Fo-Fc electron-density maps (red and green at -3σ and 3σ) 
of the LV loop region in VcDapE
T
.   
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oxygen atoms OD1 of D101 and OE1 of E164 as well as a nitrogen atom NE2 of H68.  
Zn2 adopts a distorted trigonal bipyramidal geometry and is coordinated by the bridging 
O2 oxygen atom from ethylene glycol, a nitrogen atom NE2 of H239, two oxygen atoms, 
OD2 from D101 and OE2 from E136, and the O1 oxygen atom of ethylene glycol (Figure 
3D).  The Zn1-Zn2 distance is 3.39 Å. 
Molecular Modeling and Dynamics—MD calculations were performed for five 
proteins: VcDapE
T
, HiDapE
T
, WT-VcDapE, WT-HiDapE and AAP.  After equilibration, 
the rmsd values for the main-chain atoms of [ZnZn(VcDapE
T
)] and [ZnZn(HiDapE
T
)] 
were compared with the original X-ray structures and only small changes were observed.  
Similarly, small changes were seen after equilibration of VcDapE and HiDapE as well as 
AAP, which is monomeric and contains a single catalytic domain.  Since only the two 
truncated proteins were catalytically inactive, particular attention was given to how these 
proteins differed from the other three.  Figure 4 shows the results of the 5 ns molecular 
dynamics simulations of the truncated proteins and comparisons to their crystallographic 
temperature factors.  The thickness of the line indicates the flexibility of the structure at a 
given point during simulation (Figure 14A and B).  The portions of [ZnZn(VcDapE
T
)] that 
have the greatest flexibility are the created dimerization domain loop which was excised 
and the active site loop V (Figure 13).  This is consistent with the crystallographic atomic 
displacement parameters indicating that the most dynamic portions includes residues 177-
187 and loop V (Figure 14C).  Compared to the other three structures, the two truncated 
proteins have greater flexibility in both of these loops (Figure 14) than the catalytically 
active domains (Figure 15). 
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Mutation of the Loop V Residue T325—Since both X-ray crystallographic and 
MD simulations suggested that loop V flexibility increases in VcDapE
T
 and HiDapE
T
, it 
was hypothesized that this loop plays an important role in constituting the active site and 
possibly substrate recognition and/or transition-state stabilization.  Since T325 in HiDapE 
is centrally positioned in loop V directly above the dinuclear Zn(II) site (Figure 16), the 
site-directed mutants T325A, T325S and T325C were prepared and purified.  The kcat 
value obtained for T325A using L,L-SDAP as the substrate was 4 ± 0.5 s
-1
 with a 
corresponding Km value of 2.1 ± 0.2 mM while the kcat value obtained for T325S was 2.9 
± 0.3 s
-1
 with a Km value of 3.0 ± 0.3 mM.  Interestingly, when T325 was replaced by 
cysteine, no enzyme activity was observed under standard assay conditions.  CD spectra 
obtained for each mutant enzyme plus WT-HiDapE, indicate that there is no significant 
structural change in the mutant enzymes compared to WT-HiDapE (Figure 17, Table 3).  
These data confirm that T325 and hence the position of loop V is important for the active 
site organization and catalysis.   
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Figure 14.  Diagrams showing regions of flexibility in truncated DapE proteins.  (A) 
MOLMOL diagram of [ZnZn(VcDapE
T
)] molecular dynamics.  (B) MOLMOL diagram 
of [ZnZn(HiDapE
T
)] molecular dynamics (the thickness of the line is proportional to the 
variation of the protein structure during the simulation).  The crystallographic 
temperature factors indicating that the most dynamic (in red) and the most rigid (in blue) 
parts of the protein : (C) [ZnZn(VcDapE
T
)].  (D) [ZnZn(HiDapE
T
)].   
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Figure 15. Molecular dynamic simulations showing regions of flexibility in catalytic 
domain.  (A) [ZnZn(VcDapE)].  (B) [ZnZn(HiDapE)]. (C) AAP.  The thickness of the 
line is proportional to the variation of the protein structure during the simulation. 
AS indicates the active site area, LVeq. equivalent of the LV loop in HiDapE). 
 
 
 
Figure 16.  The active site of WT-HiDapE showing loop V.  T325 resides on loop V 
directly over the dinuclear active site. 
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Figure 17. Circular Dichroism spectra of WT DapE (—), T325A (∙∙∙), T325C ( - ) and 
T325S (-∙∙∙). 
 
 
Table 3. Circular dichroism spectroscopy analysis of WT DapE and threonine mutants. 
 
  Helix 1 Helix 2 Strand 1 Strand 2 Turns Unordered Total 
Wild 
Type 0.24 0.05 0.20 0.12 0.17 0.23 1.01 
T325A 0.23 0.07 0.19 0.12 0.15 0.23 0.99 
T325C 0.23 0.05 0.18 0.12 0.19 0.22 0.99 
T325S 0.30 0.06 0.17 0.11 0.14 0.21 0.99 
Results are shown as proportions of each protein predicted to be folded in each of the 
indicated secondary structural conformations, or predicted to be unordered. 
 
 
Discussion 
Sequence comparison of all M20 classified metallopeptidases and the M28 family 
of dinuclear Zn(II)-dependent metalloproteases, which include AAP and CPG2 
62, 64
,  
shows  that all of the metal coordinating residues are strictly conserved.
53, 67b, 79
.  Unlike 
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AAP, which is monomeric, DapE enzymes form dimers where each subunit consists of 
two functional domains: a larger catalytic domain, which houses the active site and a 
dimerization domain that forms the dimer interface (Figure 12A).  The location and 
architecture of the catalytic domain and the dinuclear Zn(II) active site in dimeric WT-
HiDapE is nearly identical to the catalytic domain and the active site of monomeric 
AAP.
64a, 80
  The catalytic domain of HiDapE is composed of residues 1–179 and 293–376 
where the core of the catalytic domain contains an eight-stranded twisted β-sheet that is 
sandwiched between seven α-helices.  The active site is located in the center of the 
catalytic domain above the centrally located parallel strands of the -sheet and is 
constituted by six loops.  With the exception of loop V that encloses the active site from 
the top and does not interact with the zinc ions, the remaining loops contribute the 
conserved residues that coordinate the metal ions (Figure 12B).  The dimerization domain 
of HiDapE consists of a 114-residue insertion into the catalytic domain and is connected 
to the catalytic domain by two short loops.  Since the dimerization domain is located 
away from the active site and has only limited interaction with the catalytic domain via 
loop V, it is unclear whether this domain plays any role in catalysis.  Such a role for the 
dimerization domain would require a major conformational change to bring the 
dimerization domain residues into the active site.  While this is possible, the time frame 
would be well beyond the range of atomistic MD simulations. 
To address this issue we engineered DapE enzymes by removing their 
dimerization domains (HiDapE
T
, VcDapE
T
).  The nested truncation was designed based 
on WT-HiDapE crystal structures with the goal of preserving the catalytic domain 
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structure and keep its active site intact.  The HiDapE
T
 and VcDapE
T
 constructs expressed 
well, were purified, the monomeric states of both proteins in solution was confirmed and 
their catalytic activities examined.  Surprisingly, we could not detect enzyme activity for 
either truncated variant towards L,L-SDAP, whereas WT-HiDapE exhibited kcat and Km 
values in good agreement with those previously reported.
67b
  For comparison purposes, 
the kcat and Km were also determined for WT-VcDapE and found to be similar to the 
values reported for WT-HiDapE.  These data suggest that the deletion mutants have 
significantly diminished catalytic activity or are fully catalytically inactive.   
To understand the structural basis of the observed absence of catalytic activity of 
both engineered enzymes, we determined the crystal structures of the truncated forms of 
HiDapE
T
 ([ZnZn(HiDapE
T
)]) and VcDapE
T
 ([ZnZn(VcDapE
T
)]) along with the apo-form 
of VcDapE
T
.  These structures reveal that the catalytic domain is indeed unchanged, 
including complete structural preservation of the catalytic site and metal core.  It is clear 
that deletion of the dimerization domain does not compromise the catalytic domain 
structure.  The structure of [ZnZn(HiDapE
T
)]
 
is virtually identical to the catalytic domain 
the WT-HiDapE with an rmsd of 0.8 Å for 248 equivalent C atoms.  Interestingly, the 
newly determined structure of [ZnZn(VcDapE
T
)] also shows high similarity to the 
catalytic domain of WT-HiDapE
 
with an rmsd of 1.15 Å for 246 equivalent C atoms.  
Since the structures of VcDapE
T
 were determined in both the apo- and dinuclear Zn(II)-
loaded forms, it is evident that removal of either the dimerization domain or the metal 
cations does not alter the overall structure of the catalytic domain.  The dinuclear Zn(II) 
active sites in both HiDapE
T 
and VcDapE
T
 are nearly identical to each other with Zn-Zn 
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distances of ~3.40 Å.  These Zn-Zn distances are comparable to those observed for AAP 
(3.45 Å), HiDapE (3.33 Å) and carboxypeptidase G2 (CPG2) (3.25 Å).
64b, 79b
  Similar to 
AAP, HiDapE, and CPG2 one of the Zn(II) ions in [ZnZn(VcDapE
T
)] adopts a distorted 
tetrahedral geometry while the second Zn(II) ion is trigonal bipyramidal.  Identical to 
CPG2, HiDapE, and AAP each zinc ion is coordinated by one imidazole group (H68 for 
Zn1 and H239 for Zn2) and the oxygen atoms of E164 for Zn1 and E136 for Zn2.  Both 
zinc ions are bridged by D101 and a single oxygen atom of ethylene glycol (in the 
molecule one, chain A) or water molecule (in the second molecule, chain B).  Overall the 
[ZnZn(VcDapE
T)] structure confirms that the metal ions form a (μ-oxygen)(μ-
carboxylato)dizinc(II) core similar to HiDapE, AAP, and CPG2 
81
, and indicates that the 
active site catalytic unit is intact in the truncated forms of DapE.  Therefore, the lack of 
the catalytic activity is puzzling and clearly is not due to missing a key element in the 
HiDapE
T
 and VcDapE
T
 dinuclear active site.  
Comparison of the [ZnZn(HiDapE
T
)] and [ZnZn(VcDapE
T
)] structures with that 
of WT-HiDapE (PDB ID 3IC1) (Figure 12C & 13B) reveals that one of the six loops 
comprising the catalytic core, loop V (residues 210-214 in HiDapE
T 
and 211-215 in 
VcDapE
T
, and corresponding to 321-325 in HiDapE) exist in significantly different 
orientations than that observed in WT-HiDapE.  Interestingly, this loop is also partially 
disordered in the structure of HiDapE
T
, while in  VcDapE
T
 structures its conformational 
flexibility is signified by the double conformation of  the main chain Gly 213  (peptide 
flip).  In our previous studies, we proposed that this loop might be involved in the 
positioning and stabilization of the substrate in the active site, therefore the loop 
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conformation might be critical for proper substrate binding and positioning as well as 
stabilization of the transition-state during the catalytic cycle.
63
  This is supported by two 
loop V mutations (T325A, T325S) that show similar Km to WT but significantly reduced 
(25-50 times) kcat values.  These data suggest that the substrate is bound with similar 
specificity, but is not effectively presented to the catalytic core for successful catalysis.  
Since the same region is affected in both HiDapE
T
 and VcDapE
T
, where loop V is out of 
place compared to the WT-HiDapE, we hypothesized that this region is important for 
catalysis.  Both of the observed orientations and the greater flexibility of this loop 
(Figures 13B & 14) seem to be due to the lack of interactions with specific portions of the 
dimerization domain.  Several interactions may be particularly critical.  First, loop V in 
WT-HiDapE is partially held in position by the anti-parallel beta strands (β7 and β12) 
and interactions with a loop connecting β7 with the dimerization domain.  These contacts 
are missing in the truncated protein as portions of strands β7 and β12 have been 
transformed into a deletion-derived loop and  helix (Figure 13B).  Loop V in WT-
HiDapE is also held in place by the loop from the dimerization domain (residues 223 to 
228) (Figure 16).  These contacts are also missing in the truncated protein.  
Interestingly, the structure of WT-HiDapE contains a sulfate ion located at the 
interface of the catalytic and dimerization domains and positioned very closely to loop V.  
The sulfate binding may have biological relevance and might indicate region where the 
L,L-diaminopimelic acid moiety of the substrates binds.  Several residues from both 
domains interact with this sulfate ion. These include Arg178 (NE), Arg179 (NH), and 
Gly324 (amide NH; residue in loop V) from the catalytic domain and Arg258 (NH) from 
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the dimerization domain (corresponding to Arg179, Arg180, Gly325 and Arg259 in WT-
VcDapE) (Figure 16). This interaction is completely absent in the structure of the 
[ZnZn(VcDapE
T
)] and residues Arg178 and Arg179 are part of the deletion-derived 
distorted  helix, whereas Gly214 (corresponding to Gly324 in WT-HiDapE) located 
within loop V does not form any observable interactions (Figure 16).  
Another indication that the specific orientation of loop V may be crucial for 
catalysis comes from MD simulations of the truncated DapE structures compared to WT-
DapE and AAP (Figure 15).  Consistent with the large crystallographic temperature 
factors, the greatest flexibility in the truncated forms of DapE is observed in the 
engineered loop created to replace the deleted dimerization domain and loop V, which 
directly overhangs the dinuclear active site (Figure 14C and D).  For comparison, loop V 
in the apo-structure of NmDapE (PDB entry 1vgy) is well ordered and positioned such 
that it allows two arginine residues (Arg179, Arg259 corresponding to the pairs 
Arg178/Arg258 and Arg179/Arg259 in HiDapE and  VcDapE, respectively) to closely 
approach the active site.  It is highly likely that these Arg residues, which are semi-
conserved (Arg178) or conserved (Arg259) in DapEs, might interact with the carboxylate 
moieties of the substrate.  Conserved Arg residues were shown to be essential to interact 
with substrate in human aminoacylase-1 (Acy1).
82
  Interestingly in AAP, which exists as 
a monomeric protein of only the single catalytic domain, there is a loop residing directly 
over the dinuclear zinc active site that corresponds to loop V in DapE.  This loop is very 
rigid, unlike loop V in DapE, and appears to be held in place by an internal disulfide 
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bridge formed between C223 and C227 (Figure 18).  A decrease in dynamic flexibility 
due to changes in quaternary structure has been suggested for other protein.
83
 
 Apart from loop V, an additional loop might play an important role in the 
catalysis. Studies on Acy1, another dimeric member of the M20 family, showed that the 
dimerization domain contributes to the active site probably by interacting with the 
substrate.
82
  Lindner et al.
82
 showed that the alanine mutant of His206, which is located at 
the center of the loop, rendered the enzyme nearly inactive.  An equivalent histidine 
residue is conserved in DapE enzymes (H194 in HiDapE and H195 in VcDapE), but it is 
disordered in the WT-HiDapE structure.
63
  Modeling of this disordered loop region 
(Figure 12A) positions H194 roughly ~13Å from the active site core, which is likely too 
far to interact with the substrate.  However, it is possible that this loop can rearrange upon 
substrate binding as was reported for Acy1 and Sapep.
82,
 
84
   
Evidence for such a loop movement can be gleaned from the structure of apo-
NmDapE where this loop is positioned within 8 Å of the active site.  These data suggest 
that this His residue may also play an important role in DapE enzymes by interacting 
with the substrate. This hypothesis is consistent with DapEs structural design as the 
presence of the inter-domain clefts and connectors would allow for significant movement 
of this domain.  Confirmation of the role of His194 in substrate recognition and binding 
must await a structure of DapE in complex with a substrate analog. 
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Figure 18.  The role of the dimerization domain in the stabilization of loop V in WT-
HiDapE. (A). Superimposition of the WT-HiDapE (gray) and VcDapE
T
 (cyan) structures 
is shown.  Loop V of WT-HiDapE and VcDapE
T
 is labeled as HiLV and VcLV, 
respectively.  WT-HiDapE residues interacting with the sulfate ion (stick model) are 
shown as gray lines.  Corresponding residues in VcDapE
T
 (except for R258 that is absent 
in the deletion mutant) are shown as yellow (R179 and R180) and orange (G214) lines. 
 
 
 
 
 
 
 
(B) Specific orientation of the active site loop V in VcDapE
T
 and the corresponding loop 
in AAP.  Overlay of the VcDapE
T
 (cyan) and AAP (purple) structures is shown.  The 
AAP loop and VcDapE
T
 loop V are labeled as ApLV and VcLV, respectively.  
Stabilization of loop V in AAP by a disulfide bridge is indicated where Cys223 and 
Cys227 of AAP and the residues involved in zinc-binding in VcDapE
T
 are shown as 
sticks.  Zinc ions of VcDapE
T
 are shown as black spheres.  Zinc-bound ethylene glycol 
was omitted for clarity. 
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In conclusion, removal of the dimerization domain in DapE enzymes renders the 
enzyme inactive, even though the resulting truncated proteins have structures of the 
catalytic domain that are remarkably similar to WT-DapE and AAP.  In fact, the 
dinculear Zn(II) site in the truncated DapE enzymes is nearly identical to those observed 
for AAP and WT-HiDapE.  Therefore, one would expect that the active site should be 
capable of catalyzing a hydrolytic reaction and yet no activity is detected.  This suggests 
that positioning of the substrate in the active site is critical for the catalytic reaction to 
occur.  Analysis of the structures HiDapE
T
 and VcDapE
T
 reveals that loop V is much 
more flexible in the truncated enzymes than WT-DapE due to the lack of interactions 
provided by the dimerization domain.  These data suggest that the dimerization domain 
functions to restrict the conformational freedom of the loop V region and may contribute 
residues to the active site environment (H194, R179, R258, T325) that are important for 
substrate recognition, and binding.  Designing small molecules inhibitors that interact 
with this active site loop V region as well as the dinuclear metal center, or disrupting 
dimer formation may lead to more potent DapE inhibitors that can function as 
antibacterial agents. 
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CHAPTER THREE  
INHIBITION OF THE DAPE-ENCODED N-SUCCINYL-L,L-
DIAMINOPIMELIC ACID DESUCCINYLASE FROM NEISSERIA 
MENINGITIDIS BY L-CAPTOPRIL 
Introduction 
 
The discovery of penicillin in 1929 was one of the greatest advances in 
therapeutic medicine considering the dramatic decrease in morbidity and mortality.85  
Unfortunately, conventional wisdom predicted that bacterial resistance to antibiotics was 
inevitable.  The first strains of bacteria to develop resistance to penicillin were identified 
in 1940, less than 20 years after its discovery.86  Bacteria have several means of 
developing resistance to antibiotics such as mutating existing genes (point mutations, 
deletions, inversions, insertions, etc.) or by acquiring new genes from other strains 
(horizontal gene transfer).16  Therefore, the excessive and often unnecessary use of 
antibiotics in humans and animals accelerates the emergence of antibiotic resistant 
bacterial strains.30  Since, nearly all newly developed antibiotics are simply structural 
variants of previously employed antimicrobial agents, many of them targeting the same 
enzymatic pathways, the risk of bacteria quickly developing resistance is very high.4  In 
fact, several pathogenic bacteria, some of which were thought to have been eradicated, 
have made a significant resurgence due to bacterial resistance to antibiotics.4, 44  
According to the CDC, several bacterial strains currently exhibit multidrug resistance  
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with more than 60% of hospital acquired infections in the United States caused by the so-
called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter 
species).
12
   
To alleviate the problem of antibiotic resistance, it is urgent that new enzymatic 
targets in yet unexplored bacterial synthetic pathway be identified and specific inhibitors 
be developed.
87
  The meso-diaminopimelate (mDAP)/lysine biosynthetic pathway offers 
several potential antibacterial enzyme targets, such as the dapE-encoded N-succinyl-l,l-
diaminopimelic acid desuccinylase (DapE).
20, 23, 27
  The products of this pathway, mDAP 
and lysine are essential components of the peptidoglycan cell wall for Gram-negative and 
most Gram-positive bacteria, providing a link between polysaccharide strands.
2, 20, 29
 
DapE genes have been identified in a large number of pathogenic Gram-positive and 
Gram-negative bacteria including all of the ESKAPE pathogens and sequence alignment 
of these DapE genes reveals a minimum of 49% identity.
32, 37, 42, 55b, 64a, 88
  Deletion of the 
gene encoding for DapE is lethal to Helicobacter pylori and Mycobacterium smegmatis 
even in the presence of lysine supplemented media.
55
  Therefore, DapEs appear to be 
essential for bacterial cell growth and as there are no similar biosynthetic pathways in 
mammals, DapEs are potential targets for inhibitors that may possess antimicrobial 
activity.
27
  
 
DapEs are metalloenzymes that catalyzes the hydrolysis of N-succinyl-L,L-
diaminopimelic acid (SDAP), forming L,L-diaminopimelic acid and succinate.
29
  DapEs 
have been purified from multiple sources but the best characterized enzyme is the DapE 
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from Haemophilus influenzae (HiDapE), which is a homodimeric enzyme (subunit Mr = 
41.6 kDa) and requires two Zn(II) ions per mole of polypeptide for full enzymatic 
activity.
32
  The X-ray crystal structures for both the mono and dinuclear Zn(II) forms of 
HiDapE have been reported.
63
  In the dinuclear Zn(II) form, each Zn(II) ion adopts a 
distorted tetrahedral geometry coordinated by one imidazole (H67 for Zn1 and H349 for 
Zn2) and one carboxylate group (E163 for Zn1 and E135 for Zn2).  Both Zn(II) ions are 
bridged by an additional carboxylate groups (D100) and a water/hydroxide, forming a (μ-
aquo)(μ-carboxylato)dizinc(II) core with a 3.3 Å Zn-Zn distance.37  To date, few 
inhibitors of DapE enzymes have been reported and no X-ray structural data exists for a 
DapE enzyme in the presence of any inhibitor.   
The design of highly specific, tight binding inhibitors of DapE enzymes hinges on 
the potential inhibitor's ability to bind to the metal ions in the active site.  L-captopril, an 
angiotensin-converting enzyme (ACE) inhibitor, was shown to be a potent inhibitor of 
HiDapE, (IC50 of 3.3 μM and a measured Ki of 1.8 μM) and showed a dose-responsive 
antibiotic activity towards E. coli.
42
  Several factors are important for L-captopril 
interactions with the active site metal ions of DapE, some of which are metal 
coordination geometry, the open metal coordination sites (i.e. those filled by a 
water/hydroxide molecules), and the number of active site metal ions.  Therefore, we 
have analyzed the binding of L-captopril to DapE using both spectroscopic and X-ray 
crystallographic evidence.  These data provide insight into L-captopril binding to the 
active site metal ions as well as adjacent amino acid residues, affording new information 
towards the rational design of new, more potent DapE inhibitors. 
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Materials and Methods 
Materials.  D,L-α,ε-Diaminopimelic acid (98% pure), succinic anhydride and ion 
exchange resin (Dowex 50WX8−200,H+ form) were purchased from Sigma. 2-
Naphthalenesulfonic acid 1-hydrate (98%) was purchased from TCI Microcrystalline 
cellulose was purchased from Merck.  All other chemicals used in this study were 
purchased from commercial sources and were of the highest quality available.  SDAP 
was synthesized using the procedure described by Lin et al. 
59
 providing an overall yield 
of 41%.   
Cloning, expression and purification of DapE.  The HiDapE enzyme was 
expressed and purified as described previously.
89  The DapE gene from Neisseria 
meningitidis (NmDapE) was cloned into the pMCSG7 vector using the Ligation 
Independent Cloning method.
90
  The primers used were: 5’- TAC TTC CAA TCC AAT 
GCC GCA GCT GCA GCT GCA AAA GAA AAA GTG GTT TCG TTG GCA CAA G 
- 3’and 5’- TTA TCC ACT TCC AAT GTT AGT TAG CTA TCC AAT AAA TTC ACT 
AAC ATT TTG TG-3’.  The PCR product was purified using the QIAquick PCR 
Purification Kit (Qiagen) to remove the primers and dNTPs from the PCR reaction.  T4 
polymerase was employed to create overhangs on the PCR fragments.  The resulting 
plasmid was transformed into BL21(DE3)/magic E. coli competent cells and grown  in 
Luria-Bertani Broth (LB) media containing ampicillin (150 µg mL
-1
) and kanamycin (25 
µg mL
-1
) at 37 ˚C to an A600 of 0.7 with shaking.  IPTG was added (0.4 mM) and culture 
growth was continued for 16 h at 18 ˚C.  Cells were recovered by centrifugation 
(12,000g) for 15 min. at 4 ˚C using a Beckman Coulter Avanti J-E Centrifuge.  NmDapE 
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was purified according to the standard protocol for Ni-NTA affinity chromatography and 
all steps were performed at 4 ˚C.91  The His6-tag was removed by treating each enzyme 
with His6-tagged TEV protease for 16 h at 4 ˚C in 50 mM HEPES, pH 8.0. Cleaved 
protein was separated from His6-tagged TEV using Ni-NTA affinity chromatography.   
Enzymatic Assay.  The specific activity of HiDapE and NmDapE was determined 
using a 50/50 mixture of D,D and L,L-SDAP as the substrate in 50 mM Phosphate buffer 
(PPi), pH 7.5 as previously described.
67b
  The kinetic parameters Vmax and Km were 
determined by quantifying the amide bond cleavage (decrease in absorbance) of L,L-
SDAP at 225 nm ( = 698 M-1 cm-1) in triplicate.  Enzyme activities are expressed as 
units/mg where one unit is defined as the amount of enzyme that releases 1 μmol of L,L-
SDAP at 30 ˚C in 1 min.  Catalytic activities were determined with an error of ± 10 %.  
Initial rates were fit directly to the Michaelis-Menten equation to obtain the catalytic 
constants Km and kcat using Origin software. 
Inhibition of NmDapE by L-captopril.  The kinetic parameters v (velocity), kcat 
(Vmax/[E]0), Km (Michaelis constant), and Ki (inhibition constant) were determined in 50 
mM PPi at pH 7.5 spectrophotometrically by recording the initial velocity of the 
hydrolysis of L,L-SDAP at 25 
o
C in triplicate.
92
  L-captopril concentrations ranged from 
0 to 0.1 mM.  The linearity of the progress curves for product formation both in the 
absence and presence of inhibitor indicated that L-captopril is in rapid equilibrium with 
NmDapE.  The initial rates were plotted against substrate concentration and the kinetic 
constants were calculated using Origin software.
59, 67
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Co(II)-Substituted DapE samples.  Apo-DapE was prepared by extensive dialysis 
for 72 h at 4 ˚C against 10 mM EDTA in 50 mM HEPES buffer, pH 7.5.  DapE was then 
exhaustively dialyzed against metal-free (Chelex-100 treated) 50 mM HEPES buffer, pH 
7.5.  Any remaining metal ions were estimated by comparing the activity of the apo-
enzyme with a sample that had been reconstituted with Zn(II).  DapE incubated with 
EDTA typically had less than 5% residual activity after dialysis.  The mono and 
dicobalt(II)-forms of HiDapE and NmDapE were prepared using apo-DapE samples that 
were incubated with CoCl2 (99.999%; Strem Chemicals, Newburyport, MA) for 30 
minutes at 25 ˚C prior to exhaustive dialysis into Chelex-100 treated buffer as previously 
reported.
93
  
UV-Visible Measurements.  Electronic absorption spectra were recorded on a 
Shimadzu UV-2450 spectrophotometer equipped with a temperature controller (25 ˚C).  
A protein concentration of 1.5 mM in 50 mM HEPES buffer, pH 7.5 was used to obtain 
each spectrum.  The electronic absorption spectra of [Co_(HiDapE)], [CoCo(HiDapE)], 
[Co_(NmDapE)], and [CoCo(NmDapE)] were recorded in both the absence and presence 
of L-captopril, and the absorption due to apo-enzyme was subtracted.  
EXAFS Spectroscopy.  EXAFS spectra of a 1 mM sample of [ZnZn(HiDapE)] 
frozen in polycarbonate cuvets (24 x 3 x 1 mm) with a 0.025 mm Mylar window covering 
face, were collected at the Stanford Synchrotron Radiation Laboratory (SSRL) on 
beamline 7-3.  The SPEAR storage ring operated in a dedicated mode at 3.0 GeV.  The 
Si[220] crystal monochromator was detuned to 50% maximum reflectivity for harmonic 
rejection.  On beamline 9-3, a focusing mirror provided harmonic rejection.  The edge 
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regions, for multiple scans obtained on the same sample, were compared to ensure that 
the sample was not damaged by exposure to X-ray radiation.  EXAFS analysis was 
performed using EXAFSPAK software according to standard procedures, using E0 = 
9670 eV for k-scale definition. 
Electron Paramagnetic Resonance Spectroscopy.  Electron paramagnetic 
resonance (EPR) spectra were recorded at 4.5 - 35 K, 9.63 GHz (ER4116DM resonator 
with B0B1), 9.37 GHz (ER4116DM resonator with B0||B1), or 9.39 GHz (SHQ 
resonator) using 1.2 mT (12 G) magnetic field modulation at 100 kHz with phase-
sensitive detection on a Bruker EleXsys E600 spectrometer equipped with an Oxford 
Instruments ESR900 helium flow cryostat and ITC503 temperature controller.  The SHQ 
resonator has a significantly higher B1 for a given microwave power than the ER4116DM 
resonator (we estimate by a factor of about 5).  Background signals were collected on 
samples of frozen buffer and subtracted. 
Magnetic Circular Dichroism Studies.  The Magnetic circular dichroism (MCD) 
instrument consists of a JASCO J815 spectropolarimeter and an Oxford Instruments 
SM4000 cryostat/magnet.  Variable-temperature variable-field (VTVH) MCD data were 
collected at increments of 0.5 Tesla (T) from 0 to 7.0 T and at temperatures (nominally) 
of 1.5, 3.0, 6.0, 12, 24 and 48 K.  Spectra were collected at 1.0 nm band width and were 
scanned at 50 nm/min using a one second time constant.  The sample cell has a 0.62 cm 
path length.  Each spectrum was corrected for any natural CD by subtracting the zero-
field spectrum of the sample.  Even when there is no sample present the instrument the 
baseline exhibits a small deviation from zero that is both field- and wavelength-
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dependent.  Therefore, each spectrum was also corrected by subtraction of a spectrum 
recorded at the same magnetic field but with no sample present.  The MCD spectra were 
fit to the minimum number of Gaussian peaks using GramsAI 9.1 software after 
converting the spectra to wavenumber units.  In the fitting process, a minimum number of 
Gaussians were fit to achieve a satisfactory composite spectrum.  Fitting of the VTVH 
MCD data was achieved using a Fortran program, VTVH 2.1.1, written by Mark Riley.
94
  
The spin Hamiltonian and additional details of the fitting program have been described 
previously.
95
  The fits were tested for robustness once a complete set of parameters had 
been obtained.  To do this, the initial parameters were set to the best fit parameters and 
then all allowed to float. Subsequently, one key parameter such as J, D, Mxy, Mxz, Myz was 
chosen and its initial value was set differently after which the fit process was repeated.  
Percent polarization for a given fit was calculated from Mxy, Myz and Mxz using %Mx = 
(Mxy•Myz)
2
/[(Mxy•Mxz)
2
+(Mxy•Myz)
2
+(Mxz•Myz)
2
]. My and Mz were calculated 
correspondingly.
96
  Finally, the VTVH MCD data fitting program used a spin 
Hamiltonian that included the term H = -2J S1S2. 
Protein Crystallization.  Prior to crystallization, a 25 mg/ml NmDapE protein 
sample was incubated with 3 eq. of Zn
2+
 ions and left on ice for 20 minutes to equilibrate.  
Zinc-loaded NmDapE was screened against three hundred commercially available 
conditions (Index HT and PEG/Ion HT from Hampton Research and Wizard TM from 
Emerald Biosystems) using a Mosquito liquid handling robot with 96 plates.
97
  Several 
crystallization conditions were characterized yielding diffraction quality crystals.  All 
crystals were screened and data were collected on the best diffracting crystals, which 
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were grown by the sitting-drop vapor-diffusion method at 16 ˚C using 400 nl of a 
precipitant solution (20% (w/v) PEG 3350, 100 mM HEPES pH 7.5) and 400 nl of 
[ZnZn(NmDapE)].  X-ray quality crystals appeared within 2 weeks.  Crystals of 
[Zn_NmDapE] were also crystallized by the sitting-drop vapor-diffusion method at 16 ˚C 
but with a 400 nl precipitant solution (15% (w/v) PEG 3350 100 mM Succinic acid pH 
7.0) and 400 nl of a protein providing crystals within 2 weeks.  Crystals of 
[ZnZn(NmDapE)] in complex with L-captopril were obtained by mixing 400 nl of a 
precipitant solution (0.2 M ammonium acetate, 0.1 M TRIS pH 8.5, 25% (w/v) and 
polyethylene glycol 3350 in a 1:1 ratio with a solution of [ZnZn(NmDapE)]  incubated 
with a 20 mM solution of L-captopril (50 mM HEPES pH 7.5, 150 mM NaCl) with 
crystals appearing within 3 weeks.  
Structure Solutions and Refinement.  The X-ray data were collected at the 19-ID 
beamline of the Structural Biology Center at the Advanced Photon Source.
37
  All data 
were processed and scaled using HKL3000.  All structures described in this manuscript 
were determined by the molecular replacement method and refined by slight variation of 
the same protocol.  Molecular replacement searches were completed with the program 
MOLREP within the CCP4 suite using the apo-crystal structure of NmDapE as a template 
(PDB id 1vgy).
37
  The asymmetric unit of [Zn_(NmDapE)] (space group P212121) 
contains a dimer, while crystals of [ZnZn(NmDapE)] and [ZnZn(NmDapE)] in complex 
with captopril both crystallized in the C2221 space group and contained only one subunit 
of the dimer.  Several rounds of rebuilding and readjusting using COOT 
98
 and 
refinement using programs REFMAC 
99
 and PHENIX 
68
 were required to improve the 
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initial models.  The final models were refined against all reflections using the program in 
the resolution ranges except for 5% of the reflections, which were randomly selected and 
used to monitor Rfree.  The final refinement statistics are presented in Table 4.  Analysis 
and validation of all structures were performed with the aid of PROCHECK
100
 and 
MOLPROBITY.
101
 The refinement restraints for the L-Captopril structure were created 
with the assistance of the program Coot and were generated from SMILE
102
 string.  
PDB coordinates.  The atomic coordinates for [Zn_(NmDapE)], 
[ZnZn(NmDapE)]  and [ZnZn(NmDapE)] bound by L-captopril were deposited in the 
PDB with id (4O23, 4PPZ and 4PQA), respectively. 
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Table 4.  Data and Refinement Statistics for [Zn_NmDapE], [ZnZn_NmDapE] and 
[ZnZn_NmDapE]-L-captopril. 
 
Data collection statistics [Zn_NmDapE] [ZnZn_NmDapE] [ZnZn_NmDapE]-L-
captopril
 
Space group P212121 C2221 C2221 
Unit cell (Å) a = 55.3 
b =111.4,  
 c = 132.5 
a = 117, 
b =151.6  
 c = 55.5 
a = 116.9, 
b =151.5  
 c = 55.1 
Resolution (Å) 39.2-2.09 29.4-2.0 27.5-1.78 
Wavelength (Å) 0.98 Å 0.98 0.98 
Number of observed 
reflections 
204709 202836 178375 
Number of unique reflections 48738 33502 46112 
Redundancy 
b
 4.2(4.0) 6.1(5.8) 3.9(3.8) 
Rmerge
a,b
 (%) 
Rpim
a,b
 (%) 
7.4 (82.1) 
4.0 (45.7) 
8.5 (89.9) 
4.3 (59.4) 
6.5 (75.2) 
3.3(44.2) 
Completeness
b
 (%) 99.1 (96.7) 100 (100) 97.7 (99.5) 
I/σ 17.9(1.5) 22.8(1.9) 17.7(1.7) 
Phasing 
phasing method MR MR MR 
Refinement statistics 
Rcryst (%) 21.3 17.5 16.4 
Rfree (%) 24.1 20.8 19.6 
protein residues 746 374 374 
zinc/phosphate/sulfates ions 3/-/4 2/1/- 2/-/1 
solvent 380 237 284 
Rmsd from target values 
bond lengths (Å) 0.003 0.020 0.021 
bond angles (deg) 0.71 1.69 1.90 
Average B factors (Å
2
) 
protein  43.8 32.2 24.8 
Zn 32.0 23.2 17.9 
H2O 37.8 24.19 34.6 
PDB ID 4O23 4PPZ 4PQA 
Ramachandran (%)
c   
M.F./A.A. 
97.4/2.6 97.6/2/4 97.9/2.1 
a
 Rmerge = ΣhklΣi|Ii(hkl) − 〈Ihkl〉|/ΣhklΣiIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, and 〈Ihkl〉 
is the weighted average intensity for all observations i of reflection hkl. and  Rpim = Σhkl(1/(N − 
1)
1/2)Σi|Ii(hkl) −   h k l |/ΣhklΣiIi(hkl). 
b 
Numbers in parentheses are values for the highest-resolution bin. 
c
As defined by MOLPROBITY (M.F.-the most favored/ A.A additionally allowed) 
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Results 
Kinetic studies on [Zn_(NmDapE)] and [ZnZn(NmDapE)].  The kinetic 
parameters for the [Zn_(NmDapE)] and [ZnZn(NmDapE)] were determined by 
monitoring the hydrolysis of L,L-SDAP, at pH 7.5 and 25 
o
C.  For [Zn_(NmDapE)], a kcat 
value of 76 ± 10 s
-1
 and a Km value of 795 ± 20 µM was obtained.  On the other hand, 
[ZnZn(NmDapE)] exhibited a kcat of 120 ± 10 s
-1
 and a Km of 610 ± 11µM.  For 
[Zn_(HiDapE)] and [ZnZn(HiDapE)], kcat values of 80 ± 5 s
-1
 and 140 ± 10 s
-1
 were 
obtained, respectively, with corresponding Km values of 730 ± 15 µM for both enzymes 
(Table 5).  Inhibition of NmDapE by L-captopril was examined by monitoring the initial 
rates of hydrolysis of L,L-SDAP as a function of L-captopril concentration in triplicate.  
The double-reciprocal plot of velocity vs. L-captopril shows a pattern characteristic of 
competitive inhibition.  The experimental data were fit to the Michaelis-Menten equation 
for competitive inhibition reported by Cleland.
103
  The inhibition constant, Ki, for the 
binfing of L-captopril to NmDapE was found to be 2.4 ± 0.1 µM in good agreement with 
the Ki value obtained for L-captopril inhibition of HiDapE of 1.8 µM.
92
 
Electronic Absorption Spectroscopy.  Electronic absorption spectra were obtained 
for [Co_(HiDapE)], [CoCo(HiDapE)], [Co_(NmDapE)], [CoCo(NmDapE)]  in both the  
Table 5.  Kinetic constants for the [Zn_(DapE)] and [ZnZn(DapE)] from N. meningitidis 
and H. Influenzae. 
 
 
NmDapE HiDapE 
Kinetic constants Zn ZnZn Zn ZnZn 
Km (µM)  795 ± 20 610 ± 11 730 ± 15 730 ± 15 
kcat (s
-1
)  76 ± 10  120 ± 10  80 ± 5 140 ± 10 
kcat/Km (mM
-1
min
-1
)  5,700 ± 200 11,800 ± 200 6,600 ± 200 11,400 ± 200 
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absence and presence of L-captopril, since the position and molar absorptivities of the 
Co
2+
 d-d bands reflect the coordination number and geometry of the metal ions.
104
  The 
absorption due to apo-DapE was subtracted in all cases.  The spectra of [Co_(NmDapE)] 
and [CoCo(NmDapE)] recorded in the absence of L-captopril are identical to those 
previously reported for [Co_(HiDapE)] and [CoCo(HiDapE)] (Figure 19A & B).
67b
  For 
[Co_(NmDapE)] two resolvable d-d transitions are observed with λmax values of 560 nm 
(ɛ ~40 M-1cm-1) and a shoulder at 520 nm (ɛ ~30 M-1cm-1) while [CoCo(NmDapE)] also 
exhibited an absorbance bands at 560 nm (ɛ ~130 M-1cm-1) and 520 nm (ɛ ~120 M-1cm-1).  
Upon the addition of 5 eq. of L-captopril to [Co_(NmDapE)] the d-d band at 560 nm 
slightly red-shifted with little or no change in the molar absorptivity (Figure 19 A).  
However, when 5 eq. of L-captopril was added to [CoCo(NmDapE)], the λmax red-shifts 
to 590 nm while molar absorptivity increases from ~130 to 250 M
-1
cm
-1
 (Figure 19A).   
Similar spectra were recorded for [Co_(HiDapE)] and [CoCo(HiDapE)] (Figure 19B).  
The UV‐Vis spectrum of [CoCo(HiDapE)] in the presence of L‐captopril was also 
recorded from 250 to 400 nm; however, the characteristic S→Co2+ ligand‐to‐metal 
charge‐transfer (LMCT) band, which would be expected to exhibit a molar absorptivity 
of ~1000 M‐
1
cm‐
1
, was not observed due to strong protein absorption.
104
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Figure 19.  Electronic Absorption Spectra: ( A) a 1.5 mM solution of [Co_(NmDapE)] in 
50 mM HEPES buffer, pH 7.5 in the absence (black) and presence (blue) of 5 eq. of L-
captopril and a 1.5 mM solution of [CoCo(NmDapE)] in the absence (red) and presence 
(green) of 5 eq. of L-captopril in 50 mM HEPES buffer pH 7.5. 
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(B) a 1.5 mM solution of [Co_(HiDapE)] in the absence (black) and presence (blue) of 5 
eq. of L-captopril in 50 mM HEPES buffer at pH 7.5 and a 1.5 mM solution of 
[CoCo(HiDapE)] in 50 mM HEPES buffer at pH 7.5 in the absence (red) and presence 
(green) of 5 eq. of L-captopril.  The electronic absorption spectrum of apo enzyme was 
subtracted in each case.         
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EPR spectra of L-captopril bound to [Co_(NmDapE)], [CoCo(NmDapE)], 
[Co_(HiDapE)], and [CoCo(HiDapE)].  EPR spectra of the resting forms of Co
2+
-
substituted NmDapE (Figure 20A) and HiDapE (Figure 20B) show distinct similarities.  
At 13 K and non-saturating microwave power, the [Co_(NmDapE)] spectra are complex 
and appear due to a moderately rhombic (E/D  0.15) MS =  
1
/2 signal with resonances at 
g' = 5.35 (1250 G), 4.05 (1660 G) and 2.25 (3015 G), superimposed on an MS =  
3
/2 
signal with a sharp resonance at g' = 6.5 (1030 G) and a broad derivative feature with an 
estimated turning point at g'  1.15.  At 4.5 K and high microwave power, the MS  
1
/2 
signals are almost completely extinguished.  This latter behavior indicates that the MS =  
1
/2 signals are due to thermal population of the MS =  
1
/2 Kramers' doublet at the higher 
temperature and is due to an excited state with a zero-field splitting,, on the order of 10 
cm
-1
 for [Co_(NmDapE)], and less for [Co_(HiDapE)] where some  MS =  
1
/2 
contribution is still evident at 4.5 K (1 cm
-1
 corresponds to 1.44 K).  If the MS =  
1
/2 
signals were ground state signals due to a distinct chemical species, rapid-passage signals 
would be expected to be observed rather than disappearance or diminution of the 
signals.
105
  The data indicate, therefore, a preferred binding site with an MS =  
3
/2 ground 
state, suggesting a distorted tetrahedral coordination environment.
105
  Upon adding a 
second equivalent of Co
2+
, a poorly resolved and apparently MS =  
1
/2 signal is observed 
at 13 K.  In addition, a very weak but clearly identifiable 
59
Co hyperfine pattern with Az = 
90 G was observed on the low field edge of the MS =  
1
/2 signal, centered at g' = 7.9 
(850 G; see e.g. Figure 20A, trace C), that could be due to a small amount of an  
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Figure 20.  EPR spectra at 9.39 GHz (SHQ resonator) of:  (A) [Co_(NmDapE)] (A, B) 
and [CoCo(NmDapE)] (C, D), recorded at 13 K, 0.5 mW (A, C) and 4.5 K, 100 mW (B, 
D).  Spectral amplitudes are shown normalized for 1/T, Pmicrowave  , and eq. of Co
2+ 
added.  (B) of [Co_(HiDapE)] (A, B) and [CoCo(HiDapE)] (C, D), recorded at 13 K, 1.0 
mW (A, C) and 4.5 K, 200 mW (B, D).  Spectral amplitudes are shown normalized for 
1/T, Pmicrowave  , and eq. of Co2+ added. 
 
     A)                                                                              B). 
 
 
additional MS =  
3
/2 signal with greal(z) ~ 2.6 or else a very rhombic (E/D ~ 
1
/3) MS =  
1
/2 
signal with greal(y) ~ 2.9; the origin of the hyperfine-split signal is unclear but it was 
completely insensitive to captopril and is not considered further.   
In contrast to [Co_(NmDapE)] and [Co_(HiDapE)], when EPR spectra of 
[CoCo(NmDapE)] and [CoCo(HiDapE)]were recorded at 4.5 K, the predominant MS =  
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1
/2 signal was clearly still observable as a rapid-passage signal that appears as an inverted 
absorption-shaped feature, superimposed on the sharp MS =  
3
/2 signal at g' = 6.5.  The 
appearance of a slow-relaxing ground-state MS =  
1
/2 signal is consistent with the second 
added eq. of Co
2+
 occupying a five- or six-coordinate site.  There is a slight difference 
between the signals from [CoCo(NmDapE)] and [CoCo(HiDapE)].  The signal from 
[CoCo(NmDapE)] appears to account for the entire cobalt complement, whereas that 
from [CoCo(HiDapE)] indicates that some EPR silent Co
2+
 is present.  Further, the MS = 
 3/2 signal in [CoCo(HiDapE)] is specifically and significantly smaller than in 
[Co_(HiDapE)], whereas this is not the case in [CoCo(NmDapE)].  These data suggest 
weak antiferromagnetic interaction between the Co
2+
 ions in [CoCo(HiDapE)], such that 
|J| > h for some, but not all, of the population of dinuclear centers in the sample, i.e. that 
there is a distribution of J that includes 0.3 cm
-1
.  No parallel mode (B0||B1) EPR signals 
were observed. 
 L-captopril addition was found to induce differential effects in [CoCo(NmDapE)] 
and [CoCo(HiDapE)].  Upon adding L-captopril to [CoCo(NmDapE)], the sharp MS =  
3
/2 signal at g' = 6.5 is essentially extinguished but no overall signal intensity is lost 
(Figure 21, traces A & B).  This is consistent additional coordination of the hitherto four- 
coordinate Co
2+
 ion but no mediation of significant ( 0.3 cm-1) exchange coupling 
between the two Co
2+
 ions.  In contrast, the addition of L-captopril to [CoCo(HiDapE)] 
leads to a wholesale loss of about 30 % of the EPR intensity, with no detectable change in 
line shape (Figure 21, traces C & D), signifying an increase, albeit modest, in the 
exchange coupling between the two Co
2+
 ions. 
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Figure 21.  EPR spectra at 9.63 GHz (ER4116DM resonator) of [CoCo(NmDapE)] before 
(A) and after (B) the addition of L-captopril; and [CoCo(HiDapE)] before (C) and after 
(D) addition of L-captopril.  Spectra were recorded at 4.5 K, 100 mW. Spectral 
amplitudes are shown normalized for 1/T, Pmicrowave  , and eq. of Co2+ added.   
 
 
MCD spectra of L-captopril bound to [Co_(NmDapE)], [CoCo(NmDapE)], 
[Co_(HiDapE)], and [CoCo(HiDapE)].  MCD spectra of [CoCo(NmDapE)] and 
[CoCo(HiDapE)] are nearly identical in shape, band energies, and intensities (Figure 22).  
It should be noted that the MCD spectra at room temperature in pure buffer (no glycerol 
glassing agent) have the same bands as the low temperature spectra; however, they are 
much less intense and broader.  All of the bands are temperature–dependent C-terms 
arising from the paramagnetic high-spin Co
2+
 ground states.  The intense negative band at 
576 nm is asymmetric due to a small component at 559 nm in [CoCo(HiDapE)] and at 
70 
 
558 nm in [CoCo(NmDapE)].  This intense negative band along with an intense positive 
band at 532 nm are characteristic of high-spin Co
2+
 in a four-coordinate, distorted 
tetrahedral ligand field.
106
  These bands arise from the 
4
A2→
4
T1(P) d-d transition in Td 
that have been split into three components by the lower symmetry environment in the 
active site.  The negative band at 503 nm along with a very weak positive band at shorter 
wavelength are characteristic of high-spin Co
2+
 in a six-coordinate, distorted octahedral 
ligand field.
106a, b, 107
  The band at 503 nm arises from the 
4
T1g→
4
T1g(P) d-d transition in  
 
Figure 22.  MCD spectra of :  (A) [CoCo(HiDapE)] (top) and [CoCo(NmDapE)] (bottom) 
and  (B) [CoCo(HiDapE)] + 5 eq. of L-captopril (top) and [CoCo(NmDapE)] + 5 eq. of 
L-captopril (bottom).  All spectra were recorded at 1.3 K and 7.0 T in a 0.62 cm path 
length cell.  The enzymes were in a solution of 60/40 (v/v) glycerol/buffer.  
[CoCo(HiDapE)] was 32 mg/mL (0.77 mM enzyme, 1.6 mM in active sites, 3.1 mM in 
Co
2+
).  [CoCo(NmDapE)] was 29 mg/mL (0.70 mM enzyme, 1.4 mM in active sites, 2.8 
mM in Co
2+).  The units of Δε/H are M-1cm-1T-1, where the concentration of actives sites 
was used.  In both figures the blue trace is the experimental spectrum and the red traces 
are the Gaussians used to fit the spectra. 
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Oh that can broaden or split in lower symmetries.  The 503 nm band does not split in 
[CoCo(NmDapE)] or [CoCo(HiDapE)] but is noticeably broader in [CoCo(HiDapE)] than 
in [CoCo(NmDapE)].  The very weak positive bands at 463 and 475 nm in  
[CoCo(HiDapE)] and [CoCo(NmDapE)], respectively, are doublet transitions, which gain 
intensity through spin-orbit coupling to the nearby spin-allowed 503 nm band.
107a
 Despite 
the similarity in the MCD spectra of [CoCo(HiDapE)] and [CoCo(NmDapE)], there is a 
difference in the relative metal binding affinities between the two enzymes.  When 1 eq. 
of Co
2+
 is added to apo-NmDapE, both the six-coordinate and four-coordinate sites are 
partially occupied.  Addition of a second eq. of Co
2+
 saturates both binding sites.  On the 
other hand, addition of 1 eq. of Co
2+
 to apo-HiDapE saturates the four-coordinate site 
leaving the six-coordinate site virtually empty.  
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VTVH MCD data were collected at 503, 532 and 576 nm on both 
[CoCo(NmDapE)] and [CoCo(HiDapE)].  The data were used to construct magnetization 
plots.  The VTVH MCD were fitted as previously described 
88a, 94
, which yield the 
electronic ground state parameters for magnetic exchange coupling (J), axial (D) and 
rhombic (E) zero-field splitting (ZFS).  Multiple experiments were run and average 
values of these parameters along with the standard deviations are given in Table 6.  
Magnetic exchange coupling, if it occurs, will be strongest through the monoatomic 
bridges (e.g. μ-1,1 as opposed to μ-1,3).  In none of the fittings of the VTVH data from 
[CoCo(NmDapE)] or [CoCo(HiDapE)] was the quality of fit improved (lower value of χ2) 
by having a non-zero J (positive or negative).  This strongly suggests that the bridging 
oxygen atom is in the form of a μ-aqua as opposed to a μ-hydroxo. Many dicobalt(II) 
complexes with either a μ-aqua or μ-hydroxo have been studied.29, 108 Aqua bridged 
complexes consistently exhibit a small antiferromagnetic coupling (negative J) or no 
coupling at all; whereas, hydroxo-bridged complexes consistently have a small 
ferromagnetic (positive J) coupling.  The ZFS parameters that were determined in the 
fitting of the VTVH data from [CoCo(NmDapE)] and [CoCo(HiDapE)] were also 
consistent with assignment of the 503 nm band to a six-coordinate Co
2+
, and the 532 and 
576 nm bands to a four-coordinate Co
2+
.  Generally the axial ZFS parameter, D, is greater 
than 50 cm
-1
 for six-coordinate high-spin Co
2+
 and less than 10 cm
-1
 for four-coordinate 
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Table 6. VTVH MCD Fitting Parameters. 
 
 
Parameter 
 
[CoCo(NmDapE)] 
a 
[CoCo(NmDapE)] 
+ Captopril
b 
 
[CoCo(HiDapE)]
c 
[CoCo(HiDapE)] 
   + Captopril
d 
J (cm
-1
) 0 -0.1 0 -0.05 ±0.04 
D (cm
-1
), 4C 3.7 ±0.6 0.05 3.7 ±1.0 4.1 ±1.5 
E/D, 4C ~0 0.002 ~0 0.25 ±0.14 
D (cm
-1
), 6C >100 >50 >100 28 ±5 
E/D, 6C 0.18 ±0.04 ~0 0.27 ±0.04 0.08 ±0.03 
     
Polarizations 503 nm x-pol. 505 nm na 503 nm x-pol. 505 nm z-pol. 
 532 nm xy-pol. 530 nm na 532 nm xy-pol. 530 nm z-pol. 
 576 nm xy-pol. 604 nm z-pol. 576 nm xy-pol. 604 nm z-pol. 
a
Based on 3 independent experiments; ± one standard deviation.  
b
Based on a single experiment. 
c
Based on 
8 independent experiments. 
d
Based on 4 independent experiments. 
 
high-spin Co
2+
.
29, 106c
  The addition of 1 eq. (based on concentration of active sites) of L-
captopril to either [CoCo(HiDapE)] or [CoCo(NmDapE)] has no apparent effect on the 
MCD spectra.  However, addition of 5 eq. of L-captopril causes the green resting enzyme 
solutions to turn blue (Figure 22B).  The four-coordinate Co
2+
 bands shift from 532, 559 
and 576 nm in [CoCo(HiDapE)] to 530, 565 and 604 nm in the [CoCo(HiDapE)]-L-
captopril complex while the four-coordinate Co
2+
 bands shift from 532, 558 and 576 nm 
in [CoCo(NmDapE)] to 530, 565 and 604 nm in the [CoCoNmDapE]-L-captopril 
complex.  The six-coordinate band at 503 nm splits into two bands at 488 and 505 nm for 
both [CoCo(HiDapE)]-L-captopril and [CoCo(NmDapE)]-L-captopril.  There is a small 
peak at 576 nm in both spectra, which is due to uncomplexed enzyme.  In addition to 
these band shifts, there is a roughly three-fold decrease in MCD intensity, which is not 
due to any removable of metal from the enzyme by L-captopril.  Finally the quality of the 
optical glasses formed in the presence of L-captopril was not as high as for the resting 
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enzyme alone.  This resulted in MCD spectra that had considerably lower signal to noise 
than in the MCD spectra of the resting enzymes. 
VTVH MCD data were also collected on the 505, 530, and 604 nm bands in 
[CoCo(HiDapE)]-L-captopril and only for the 604 nm band in [CoCo(NmDapE)]-L-
captopril.  Example magnetization plots and fits are shown in Figures SI-9 through SI-12.  
The χ2 values for the 505 and 530 nm band fits are quite high as is the χ2 value for the 
604 nm band fit in [CoCo(NmDapE)]-L-captopril.  The best fits were obtained with a 
small negative value for J.  In addition the ZFS parameters for both the six- and four-
coordinate sites changed, but are still in the ranges expected for four- and six-coordinate 
Co
2+
 (Table 6).  
EXAFS of L-captopril bound to [ZnZn(HiDapE)].  Zn K-edge extended X-ray 
absorption fine structure (EXAFS) spectra were recorded for [ZnZn(HiDapE)] in the 
presence of L-captopril (Figure 23).  The EXAFS data reveal an average of both metal 
ion environments.   The dominant peak in the Fourier transformed (FT) EXAFS data for 
[ZnZn(HiDapE)] is centered at ~2.0 Å with a second shell feature at ca. 3.3 Å, identical 
to previously reported EXAFS data.
81
  Coordination of L-captopril to [ZnZn(HiDapE)] 
results in EXAFS spectra that can be fit to 5 ± 1 N/O scatterers.  However, the Zn-Zn 
distance increases from 3.32 to 3.40 Å.  In addition, the EXAFS data for 
[ZnZn(HiDapE)]-L-captopril reveal a new feature at 2.3 Å that is highly characteristic of 
a direct zinc-sulfur interaction.   
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Figure 23.  Zn K-edge EXAFS spectra of a 1 mM solution of [ZnZn(HiDapE)] 50 mM 
HEPES buffer, pH 7.5 in the absence (red) and presence (black) of L-captopril. 
 
 
Crystal structures of [Zn_(NmDapE)],[ ZnZn(NmDapE)], and the L-captopril 
bound [ZnZn(NmDapE)] complex.  The X-ray crystal structures of [Zn_(NmDapE)], (2.1 
Å), [ZnZn(NmDapE)] (2.0 Å) and the [ZnZn(NmDapE)]-L-captopril complex (1.8 Å) 
were solved.  These three structures along with apo-NmDapE, which was previously 
determined (1vgy) 
109
, reveals the typical two-domain homodimer structure (either 
present in the asymmetric unit, or generated by the crystallographic two-fold axis) 
observed for all DapE enzymes.  Comparison of all four structures of NmDapE shows 
that the overall fold is well preserved and the structures of the apo, mono and di-zinc, and 
L-captopril bound forms are nearly identical.  Each of these structures overlay with an 
rmsd for Cα atoms of 0.59 Å (apo-NmDapE over [Zn_(NmDapE)]) and 0.73Å (apo-
NmDapE over [ZnZn(NmDapE)] and L-captopril bound [ZnZn(NmDapE)]).  Close 
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analysis of the [ZnZn(NmDapE)] and [ZnZn(NmDapE)]-L-captopril structures (both were 
determined from isomorphous crystals grown under similar conditions (Table 4), reveals 
that inhibitor binding does not introduce any significant changes in the structure as 
evidenced by a very low rmsd deviation of 0.2 Å.  Furthermore, analysis of the active site 
regions of the [ZnZn(NmDapE)] structure indicates that the metal ions and ligands are in 
nearly identical positions.  The dinuclear Zn
2+
 active sites in both [ZnZn(NmDapE)] and 
the [ZnZn(NmDapE)]-L-captopril complex adopt identical coordination geometries to 
that reported for HiDapE.
37
 
For [ZnZn(NmDapE)], the first metal binding site, Zn1, resides in a distorted 
tetrahedral geometry and is bound by the carboxylate oxygen atoms OD1 of D101 and 
OE1of E164 as well as a nitrogen atom NE1 of H68.  The Zn2 metal ion resides in a 
distorted trigonal bipyramidal geometry and is bound by a nitrogen atom NE2 of H350, 
two oxygen atoms, OD2 from D101 and OE2 from E136, and the O1 oxygen atom of 
ethylene glycol.  Interestingly, for [Zn_(NmDapE)] a full dimer resides in the asymmetric 
unit and Zn
2+
 binding is different between the two active sites.  In one of the active sites, 
a single Zn
2+
 ion is bound in the first metal binding site while in the second active site 
site, two Zn
2+
 ions are present but with occupancies modeled at 50% for Zn1 and 20% for 
Zn2.  These data suggest that metal binding is not sequential for NmDapE, which is 
different from that observed for HiDapE. 
The structure of the [ZnZn(NmDapE)]-L-captopril complex was obtained by co-
crystallization of [ZnZn(NmDapE)] and L-captopril and solved to 1.8 Å resolution.  The 
structure reveals clear electron density corresponding to L-captopril inside the positively 
77 
 
charged grove, formed between the catalytic and the dimerization domains (Figure 24).  
The sulfhydryl group of L-captopril bridges between the two active site Zn
+2
 ions with a 
Zn-S distance of 2.3 Å and a Zn2-S distance of 2.3 Å, displacing the bridging water 
molecule.  The carboxy-end of the proline moiety of L-captopril forms a hydrogen bonds 
with N346 (ND2-O3, 3.0 Å) and the amide of G325 (N-O2, 2.9 Å).  It also forms a strong 
hydrogen bond with the hydroxyl of Y198 (OH-O3, 2.5Å), which reaches over from the 
second subunit of the dimer.  The O1 carbonyl oxygen of the L-captopril (the carbonyl 
oxygen of the peptide bond) also forms a hydrogen bond with a well-ordered water 
molecule (2.8Å), which is stabilized by its interaction with R179 (NH2-O 3.1 Å) and 
P165 (2.6 Å) 
Discussion 
Because of the emergence of bacterial resistance to antibiotics used in current 
standard of care, new small molecules need to be designed and synthesized that inhibit 
novel antibacterial enzyme targets, such as DapE.  Several structural classes that 
containing different zinc-binding groups (ZBG’s) such as carboxylic acids, boronic acids, 
phosphates, and thiols have been reported to inhibit DapE enzymes.  Thiols are 
commonly used as inhibitors for Zn
2+
 metalloproteins since Zn(II) is a soft acid and thiols 
are soft bases.
110
  Examination of several thiol based compounds has led to the 
identification of low micromolar inhibitors of DapE.
81, 92
  For example, L-penicillamine 
exhibits an  C50 value of 13.7 μM, and is a competitive inhibitor of HiDapE with a 
measured Ki of 4.6 μM.  DapE is also stereoselective with respect to the recognition of 
substrate and inhibitors, as D-penicillamine provided an  C50 value of 50 μM.92   
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Figure 24.  Structure of [ZnZn(NmDapE)] bound by L-captopril.  (A) Ribbon diagram of 
the homodimer of [ZnZn(NmDapE)] (subunit A in orange and subunit B in blue).  The 
Zn
2+
 ions in the dinuclear active site are shown as black spheres while molecules of L-
captopril are shown as green sticks.  (B) Close-up of the active site region showing the 
hydrogen bonding interactions of L-captopril (green) with surrounding protein residues 
and solvent molecule (red sphere).  The active site residues are color coded (orange and 
blue sticks) according to the subunit coloring, while the conserved residues binding to the 
Zn
2+
 ions are grey.  (C) Schematic drawing of the dinuclear Zn
2+
 active site bound by L-
captopril (distances are displayed in angstroms). 
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Similarly, L-captopril, and angiotensin-converting enzyme (ACE) inhibitor, exhibited an 
 C50 value of 3.3 μM towards HiDapE and is also a competitive inhibitor with a 
measured Ki of 1.8 μM while D-captopril yielded an  C50 value of 42 μM.  Similar to 
HiDapE, L-captopril is a competitive inhibitor of NmDapE with a measured Ki of 2.8 μM.  
Interestingly, it has been showed recently by Uda et al. that L-captopril targets only the 
Zn
2+
-metallo-isoform of the enzyme, whereas the Mn
2+
-enzyme was not inhibited. Since 
the Mn
2+
-substituted isoform is also physiologically relevant in bacteria, it is important 
while designating inhibitor compounds, as it has implications in substrate and ligand 
binding at the active site in vivo.
111
 Even though L-captopril is a tight binding inhibitor of 
DapE enzymes and is a promising lead compound for the development of a novel class of 
DapE inhibitors, no information exists on how L-captopril binds to DapE, a requirement 
for the rational design of new, more potent DapE inhibitors.  
Evidence of L-captopril binding to the dinuclear active site of DapE was gleaned 
from spectroscopic data obtained on the L-captopril complexes of the Co
2+
-substituted 
forms for both HiDapE and NmDapE ([Co_(NmDapE)], [CoCo(NmDapE)], 
[Co_(HiDapE)] and [CoCo(HiDapE)]).   Electronic absorption spectra suggest that the 
Co
2+
 ions bound to both HiDapE and NmDapE reside in either a distorted five- or six-
coordinate site.
67b
  Upon the addition of L-captopril to either [CoCo(NmDapE)] or 
 [CoCo(HiDapE)], results in UV-Vis spectra where the λmax is red-shifted by ~30 nm 
while the molar absorptivities increase by ~120 M
-1
cm
-1
 (Figure 19)  The observed 
changes upon L-captopril binding to the Co
2+
-forms of both NmDapE and HiDapE, 
suggest that L-captopril interacts with both active site Co
2+ 
ions.   
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Interestingly, EPR spectra of [Co_(NmDapE)] and [Co_(HiDapE)] suggest the 
Co
2+
 ion resides in a distorted tetrahedral coordination geometry at low temperature since 
an MS =  
3
/2 signal persists between the temperatures of 4.5 and 13K, characterized by a 
spike at g' ~ 6.5 (Figure 20).
67b
  The fact that the presence of a feature at 13 K due to an 
MS =  
1
/2 transition is almost completely extinguished at 4.5 K and high microwave 
powers, renders the five- or six-coordination geometry highly unlikely and is explained 
by thermal population of the MS =  
1
/2  Kramers’ doublet.  EPR spectra of 
[CoCo(NmDapE)] and [CoCo(HiDapE)] indicate a five- or six-coordinate Co
2+
 ion in the 
second binding site due to the  slow-relaxing ground state MS =  
1
/2 signal present at 
both high and low temperatures and reveal substantial line-broadening at the low-field 
line upon binding the second Co
2+
 ion, suggesting an increase of geometric flexibility 
within the second Co
2+
 binding site.
67b
  The EPR data also suggest an antiferromagnetic 
interaction due to the formation if a spin-coupled species with |J| >> 0.3 cm
-1 
between the 
Co
2+
 ions in [CoCo(HiDapE)].
67b
  Some of the Co
2+
 appears to be EPR silent and the MS 
=  3/2 signal is significantly diminished in [CoCo(HiDapE)] compared to 
[Co_(HiDapE)] which is not the case for [CoCo(NmDapE)].  The addition of L-captopril 
to [CoCo(NmDapE)] and [CoCo(HiDapE)] essentially extinguished the MS =  
3
/2 signal; 
however, the other signals are unperturbed, indicating that the tetrahedral species has 
gained a ligand (Figure 21).  On the other hand, the addition of L-captopril to 
[CoCo(HiDapE)] abolishes the EPR intensity suggesting that the spin-coupling between 
the two Co
2+
 ions increases upon L-captopril binding indicative of a thiolate bridge 
between the two active site Co
2+
 ions. 
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Additional electronic information on [CoCo(NmDapE)] and [CoCo(HiDapE)] and 
their L-captopril complexes was derived from MCD data (Figure 22).   For both 
[CoCo(NmDapE)] and [CoCo(HiDapE)] characteristic bands for high-spin Co
2+
 in a 
distorted tetrahedral and distorted octahedral ligand field are observed, consistent with 
EPR data.  An interesting finding is that despite the similarity in the MCD spectra 
between [CoCo(NmDapE)] and [CoCo(HiDapE)], the spectra obtained for 
[CoCo(NmDapE)] reveals that both the four- and six-coordinate sites are occupied upon 
the addition of only 1 eq. of Co
2+ 
suggesting a cooperative binding model for NmDapE  
that is not observed for HiDapE.  This finding is consistent with EPR data as well as the 
X-ray crystal structure of [Zn_(NmDapE)] where one of the active sites contains a Zn
2+
 
ion bound in the first metal binding site while in the second active site contains two Zn
2+
 
ions with occupancies modeled at 50% for Zn1 and 20% for Zn2.  Correlation of the 
observed ZFS with coordination number was used as a coordination number indicator 
(referred to as the CN/ZFS correlation).  In the CN/ZFS correlation, four-coordinate Co
2+
 
exhibits ZFS < 13 cm
-1
, five-coordinate between 20 and 50 cm
-1
, and six-coordinate > 50 
cm
-1
.
112
  The ZFS parameters determined from fits of VTVH data for [CoCoNmDapE] 
and [CoCoHiDapE] are consistent with four-coordinate and six-coordinate Co
2+
 centers 
in the active site.  Based on previously published magnetic properties of several μ-aqua 
μ-hydroxo dicobalt(II) model complexes, weak to moderately strong antiferromagnetic 
coupling would be expected from a single oxygen atom bridge.
113
  Fitting of the VTVH 
data from [CoCoNmDapE] and [CoCoHiDapE] strongly suggest that the bridging atom is 
in the μ-aqua as opposed to a μ-hydroxo form.  
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Upon the addition of L-captopril to [CoCoNmDapE] and [CoCoHiDapE] the 
bands shift for both the four- and six-coordinate Co
2+
 ions and a decrease in the MCD 
intensity is also observed (Figure 22).  These data are consistent with the thiol of L-
captopril bridging between the two active site Co
2+
 ions producing an 
antiferromagnetically coupled dicobalt(II) center with an S = 0 ground-state.  The overall 
changes strongly suggest that the L-captopril displaces the bridging water molecule and 
binds to both metals through a monatomic bridge that exhibits a lower ligand field 
strength than that of water.  These data are consistent with EPR data and also EXAFS 
spectra for [CoCoHiDapE] bound by L-captopril.  Upon binding L-captopril, the Zn-Zn 
distance increases by 0.08 Å and a new feature at 2.3 Å appears that is highly 
characteristic of a direct zinc-sulfur interaction.  Taken together, these data indicate that 
L-captopril interacts with both metal ions and strongly suggests the replacement of the 
bridging water molecule with a more strongly bound ligand such as the thiol functionality 
of L-captopril. 
A major limitation in developing a previously undescribed class of antimicrobials 
that target DapE enzymes is the lack of knowledge about inhibitor binding to the DapE 
active site including potential residues involved in substrate recognition and binding.  
While the spectroscopic studies suggest that L-captopril bridges between the two active 
site metal ions in DapE in solution via a μ-thiolate moiety, these data provide no detailed 
information regarding any interaction of the remaining functional groups of L-captopril 
with the active site.  In order to further characterize the binding of L-captopril to DapE, 
the [ZnZn(NmDapE)] enzyme was crystallized in the presence of L-captopril and the X-
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ray crystal structure was determined to 1.8 Å resolution (Figure 24).  As predicted by the 
EPR, MCD, and EXAFS data, no active site ligands are displaced upon L-captopril 
binding except the water molecule that bridges the two Zn
2+
 ions in the wild-type 
structure.  This bridging water molecule is displaced by the thiol sulfur of L-captopril 
with Zn1-S and Zn2-S distances 2.3 Å.  L-captopril binding also increases the Zn-Zn 
distance from 3.3 Å to 3.4 Å.  The binding of L-captopril to the dinculear active site of 
[ZnZn(NmDapE)] provides the first structural data for an inhibited form of any DapE 
enzyme providing a model for inhibitor design as well as enzyme-substrate interactions.    
DapE enzymes have strict specificity for the L,L-isoform of SDAP.
67b
  This 
specificity is built into the active site that includes both the dinuclear metal cluster as well 
as adjacent amino acid residues that form a substrate binding pocket.  Several studies 
indicate that substrate binding pockets play an important role in substrate recognition and 
binding for metallohydrolases.
41a, 114
  Inspection of the X-ray crystal structures of 
[Zn_(NmDapE)] and [ZnZn(NmDapE)], combined with surface analysis, reveals a smile-
shaped cavity that extends along the catalytic domain and surrounds the active site.  This 
well-defined and negatively charged cavity is shaped from the top by strand 12 and 8 
and in the middle by the loop connecting these two elements.  The bottom of the cavity is 
formed by a loop connecting -strands 6 and 7, and a loop connecting 5 and 4.  
Taking into account the linear character of the substrate, it is likely that the substrate 
binds in an extended conformation, lining up along the grove with the peptide bond 
positioned over the active site metals.  Insight into the role of this cavity comes from the 
[ZnZn(NmDapE)]-L-captopril structure as several interactions between the inhibitor and 
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residues within this cavity are formed.  The O1 carbonyl oxygen of the L-captopril  (the 
carbonyl oxygen of the peptide bond) forms a hydrogen bond with a well-ordered water 
molecule (2.8Å), which is stabilized by R179 (NH2-O; 3.1 Å) and P165 (2.6 Å).  In 
addition, the carboxy-end of the proline moiety of L-captopril is held in position by ionic 
interactions between N346 (ND2-O3; 3.0 Å) and the amide of G325 (N-O2; 2.9 Å).  
Interestingly, the carboxy group also forms a hydrogen bond with the hydroxyl moiety of 
Y198 (OH-O3; 2.5 Å), which resides on the other subunit of the dimer.  This interaction 
is of great interest, since it is first evidence of a residue from the second subunit 
interacting with an inhibitor bound to the first subunit.  This suggests a heretofore 
unknown function for the dimerization of DapE enzymes.  These data suggest that the 
dimerization domain is not only crucial for dimer formation but could also play an 
important role in substrate recognition and binding of substrate.  This is consistent with 
dimerization domain deletion mutants of HiDapE, which were inactive highlighting the 
importance of DapE dimer formation.
37
 
In summary, we have spectroscopically and crystallographically characterized the 
binding of L-captopril to DapE.  The thiol moiety of L-captopril coordinates to both active 
site metal ions in a μ-thiolate fashion.  No other inhibitor centered ligands interact with the 
active site metal ions.  Since the X-ray crystal structure of the [ZnZn(NmDapE)]-L-
captopril complex is the first structure of a DapE enzyme complexed by an exogenous 
ligand, several active site pocket residues including R179, P165, and N346 were identified 
that form hydrogen bonds to functional groups of L-captopril.  Remarkably, the Y198 
residue on subunit B was discovered to be involved in hydrogen bond formation with the 
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L-captopril inhibitor bound to the active site in subunit A.  This unforeseen hydrogen 
bonding interaction may prove crucial in the development of novel medicinal chemistry 
leads and may also be critical for catalysis.  Since L-captopril is an angiotensin-converting 
enzyme (ACE) inhibitor and a moderately strong inhibitor of DapE enzymes, 
understanding the electronic and structural properties of L-captopril binding to the active 
site of DapE provides a foundation for the design of new, more potent DapE inhibitors.   
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CHAPTER FOUR 
DISCOVERY OF NOVEL DAPE INHIBITORS THROUGH HIGH-
THROUGHPUT SCREENING 
Introduction 
Bacterial infections, some of which were thought to be eradicated, have made a 
significant resurgence due to bacterial resistance to all known antibiotics.2, 4-5, 115  
Resistance occurs because microorganisms that cause infections quickly develop ways to 
survive drugs meant to kill or weaken them through random mutation and natural 
selection.  Once a mutated gene is generated, bacteria horizontally transfer this genetic 
information by plasmid echange.4-5 Consequently, it's important to the health and general 
welfare of society to continually renew our arsenal of compounds that combat these 
pathogens.116  Ideally, such new compounds would target enzymes involved in bacterial 
cell wall synthesis or pathways involved in cell replication.117  The dapE-encoded N-
succinyl-L,L-diaminopimelic acid desuccinylase (DapE), a member of the meso-
diaminopimelate (mDAP)/lysine biosynthetic pathway, is just such as candidate as a 
novel target for the development of a new class of antibiotics.  DapE’s catalyze the 
hydrolysis of N-succinyl-L,L-diaminopimelic acid (SDAP) to diaminopimelate and 
succincate (Figure 4), both of which are required for protein synthesis and peptidoglycan 
layer formation in both Gram-positive and Gram-negative bacterial cell walls.59  Deletion 
of the gene encoding for DapE, is lethal to H. pylori and M. smegmatis, even in the  
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presence of lysine supplemented media.
55
  Therefore, DapEs are essential for cell growth 
and proliferation.  Since there are no similar biosynthetic pathways in mammals, 
inhibitors that target DapEs are hypothesized to exhibit selective toxicity against 
bacteria.
27
  
 DapE enzymes belong to the M28 family of dinuclear Zn(II)-dependent 
metalloproteases all of which contain a (μ-aquo)(μ-carboxylato)dizinc(II) core with one 
terminal carboxylate and one histidine residue at each metal site.
62
  The amino acid 
residues that function as metal ligands in the crystallographically characterized DapE 
enzymes are identical to other M28 family members, including the carboxypeptidase 
from Pseudomonas sp strain-RS-16 (CPG2) and the leucine aminopeptidase from 
Aeromonas proteolytica (AAP), which contain a terminal histidine and carboylate residue 
at each site.
28-29, 64a, 67b, 88b
  X-ray crystallographic and kinetic data obtained on the DapE 
from Haemophilus influenzae (HiDapE) indicate that the divalent metal binding sites 
bind in a sequential fashion and that the enzyme exhibits ~60% activity, based on kcat, in 
the presence of one Zn(II) ion.  These structural data provide the foundation for the 
design and synthesis of novel molecules, representing different structural classes that 
contain various zinc-binding groups (ZBGs).  Typical ZBGs include thiols, carboxylic 
acids, boronic acids, and phosphates.  High-throughput screening (HTS) has been 
successful in discovoring inhibitors for several metallohydrolases, including 
metalloform-specific inhibitors (i.e. preferentially bind to mononuclear vs. dinuclear 
forms of an enzyme).  For example, metalloform-specific inhibitors has been identified 
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using HTS for methionine aminopeptidases (MetAP), which bind one metal ion in vivo 
and are active with a variety of divalent first row transition metal ion.
118
   
 Inhibitor screening via HTS of DapE enzymes has been limited by the lack of a 
spectrophotometric assay that is amenable to HTS.  To overcome this issue, we report 
herein a reliable and reproducible spectrophotometric assay for DapE enzymes.  Utilizing 
this assay, we analyzed the binding ability of over 39,000 compounds representing 
different structural classes and containing different ZBG’s.  This approach identified five 
novel inhibitors of DapE enzymes and these lead compounds, along with several 
derivatives, were examined to determine their potential structure-activity relationships 
(SARs).
Materials and Methods 
 Reagents.  All chemicals used were purchased commercially and were of the 
highest quality available.  All metal reagents were obtained from Strem Chemicals, 
Newburyport, MA with 99.999% purity.  Stock solutions Zn(II) (10 mM) were prepared 
by dissolving the metal chloride salts (ZnCl2) in nanopure water. 
 Expression and Purification of HiDapE. Plasmid containing the HiDapE gene 
with an N-terminal His6-tag was transformed into BL21(DE3)/magic Escherichia coli 
competent cells and grown  in Luria-Bertani Broth as previously reported.
119
  The 
following steps were performed at 4 ˚C.  The DapE was purified according to the 
standard protocol for Ni-NTA affinity chromatography, as described previously.
91
 The 
His6-tag was removed by treating each enzyme with His6-tagged TEV protease for 16 h at 
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4 ˚C in 50 mM HEPES, pH 8.0.  Cleaved protein was separated from TEV using Ni-NTA 
affinity chromatography.  
 Expression and purification of L,L-diaminopimelate aminotransferase (LL-DAP-
AT) from E. coli.  The plasmid for LL-DAP-AT was kindly provided by Professor John 
C. Vederas and LL-DAP-AT was expressed and purified following the published 
procedure.
120
  Briefly, the plasmid was transformed into E. coli strain M15 (pREP4) 
(Qiagen Inc.) and grown in 2×YT medium at 37 ˚C until an OD600 of 0.7 was reached 
with shaking.  IPTG was added (1 mM) and culture growth was continued for 4 h.  Cells 
were recovered by centrifugation (12,000g) for 15 min. at 4 ˚C using a Beckman Coulter 
Avanti J-E Centrifuge. The resulting cell paste was suspended in lysis buffer (50 mM 
sodium phosphate, 300 mM NaCl, 10 mM imidazole, 10 mM 2-mercaptoethanol (pH 7.7) 
and lysed by sonication.  Next, the protein was purified according to the standard 
protocol for Ni-NTA affinity chromatography, as described previously.
91
  The column 
was washed with lysis buffer and eluted using a gradient of 50 mM sodium phosphate, 
300 mM NaCl, 200 mM imidazole, and 10 mM 2-mercaptoethanol (pH 8.0).  The protein 
was dialyzed against 200 mM NaCl, 20 mM HEPES- KOH (pH 7.6), 3 mM TCEP and 
stored at -80 ˚C until further needed.  
 Enzyme-Coupled Spectrophotometric Assay.  Testing was carried out using 96 
well plates with a total volume of 218 μl in each well.  Every well on the plate, except the 
last row, contained 50 µL of compound (final conc 95 µM) in 1.25% DMSO.  The last 
row served as a negative control and contained only 1.25% DMSO.  Second to last row 
served as a positive control and contained enzyme completely inhibited by EDTA (30 
mM).  The reaction mixture containing DapE 0.15 µM, HEPES-KOH 100 mM (pH 7.6) 
90 
 
was added to individual wells on the microplate and allowed to incubate for 10 min at 25 
˚C.  Next, 40 μl of the reaction mixture in HEPES-KOH (100 mM at pH 7.6) containing 
DapE (0.25 µM), LL-DAP-AT (1µM), 2-OG (1 mM), OAB (10 mM) was added to 
individual wells of the microplate using a 96-channel robotic liquid dispenser.  The 
reaction was then initiated by addition of 1.5 mM SDAP.  The initial absorbance was 
measured at 440 nm with a SpectraMax Plus384 microplate reader.  The final absorbance 
was measured after 3 h.   
 For the discontinuous assay, the reaction mixture containing DapE 0.15 µM, 
HEPES-KOH 100 mM (pH 7.6) was added to individual wells on the microplate and 
allowed to incubate for 10 min. at 25 ˚C.   The reaction was initiated by addition of 3.6 
mM SDAP and the reaction was allowed to proceed for 15 min. after which is was 
stopped by addition of EDTA (30 mM) via the direct addition into the well and allowed 
to incubate for 1 h.  The second part of the reaction was introduced by addition of 
HEPES-KOH 100 mM (pH 7.6), 2-OG (8.5 mM), OAB (10 mM), and LL-DAP-AT 
(3µM) and the initial absorbance was measured at 440 nm with a Spectra94 microplate 
reader and again after 3 h at the plateau region.   
 Controls on LL-DAP-AT were carried out in similar fashion using 96 well plates.  
Every well on the plate, except the last row, contained 50 µL of compound (final conc 95 
µM) in 1.25% DMSO.  The last row served as a negative control and contained only 
1.25% DMSO.  The second to last row served as a positive control and contained no LL-
DAP-AT enzyme.  Next, a reaction mixture containing HEPES-KOH 100 mM (pH 7.6), 
2-OG (8.5 mM); OAB (7 mM); DAP (2.3 mM assuming 25% of total DAP) was 
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aliquated to each well on a plate.  The reaction was initiated by addition of LL-DAP-AT 
(3µM) and the absorbance was monitored at 440 nm on a Spectra94 microplate reader. 
 High-Throughput Screening.  High-throughput screening was carried out using 
348 well plates with a total volume of 60 μl in each well.  Every well on the plate, except 
the last row, contained 20 µL of compound (final conc 12 µM) in 1.25% DMSO.  The 
last row served as a negative control and contained only 1.25% DMSO.  The second to 
last row served as a positive control and contained no DapE enzyme.  Next, 40 μl of the 
reaction mixture in HEPES-KOH (100 mM at pH 7.6) containing DapE (0.25 µM), LL-
DAP-AT (1µM), 2-OG (1 mM), OAB (10 mM) was added to individual wells of the 
microplate using a 96-channel robotic liquid dispenser.  The reaction was initiated by the 
addition of 1.5 mM of SDAP and the initial absorbance measured at 440 nm with a 
SpectraMax Plus384 microplate reader.  The final absorbance was measured after 3 h.   
Results and Discussion 
The discovery of novel inhibitors of DapE enzymes has been hindered due to the 
lack of a spectrophotometric assay that can continuously monitor, in real-time, a product 
in the visible region.
26
  The current DapE kinetic assay monitors the decrease in 
absorbance at 225 nm due to the hydrolysis of N-succinyl-L,L-diaminopimelic acid 
(SDAP), forming L,L-diaminopimelic acid (DAP) and succinate (Figure 4).  
Unfortunately, measurements performed at wavelengths in the UV region are subject to 
significant interference from other biological components, inhibitor side-chains, and 
compounds commonly used to make buffer solutions.  Therefore, such an assay is not  
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Figure 4. Reaction catalyzed by DapE.
 
 
amenable to HTS.  To overcome this issue, an enzyme-coupled continuous 
spectrophotometric assay was developed for DapE in 100 mM HEPES-KOH at pH 7.6 in 
the presence of 1.25% DMSO based on the production of the DapE product DAP.  As 
previously reported, DAP functions as a substrate for LL-diaminopimelate 
aminotransferase (LL-DAP-AT) from Arabidopsis thaliana, which can utilize DAP as an 
amino donor and 2-oxoglutarate (2-OG) as an amino acceptor, to produce 
tetrahydrodipicolinate (THDP).  Reaction of THDP with 2-aminobenzaldehyde (OAB) 
produces dihydroquinazolium (DHQ), which strongly absorbs at 440 nm (Figure 25).
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Figure 25.  Schematic for the enzyme-coupled continuous spectrophotometric assay used 
for high-throughput screening of DapE inhibitors.   
 
 
 Unfortunately, the molar absorptivity of DHQ is unknown given to its instability; 
therefore, DapE activity can only be expressed in absorbance units (AU) for this assay.  
In order to optimize this enzyme-coupled continuous spectrophotometric assay for HTS 
experiments, several control reactions were carried out.  In the absence of DapE, SDAP, 
OAB, LL-DAP-AT, or 2-OG no increase in absorbance at 440 nm was observed.  These 
data indicate that the increase in absorbance observed at 440 nm is dependent on the 
concentration of DapE, SDAP, and LL-DAP-AT verifying that the hydrolytic reaction 
catalyzed by DapE is required for the production of DHQ.  Titrations, in which the 
concentrations of DapE, SDAP, and LL-DAP-AT were systematically varied, were 
carried out by monitoring the absorbance at 440 nm in 100 mM HEPES-KOH at pH 7.6 
in the presence of 1.25% DMSO (Figure 26).  These titration data provided the optimum 
concentrations of DapE, SDAP, and LL-DAP-AT to produce the maximum absorbance at 
440 nm.  Once these concentrations were optimized, the concentrations of 2-OG and 
OAB were also systematically altered.  Interestingly, at 2-OG concentrations greater than 
1 mM, the observed absorbance at 440 nm decreased in 100 mM HEPES-KOH at pH 7.6  
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Figure 26.  Optimization of the enzyme coupled continuous spectrophotometric assay for 
high-throughput screening of DapE.  Varied concentration of DapE, L,L-SDAP, LL-
DAP-AT, OAB and 2-OG in 100 mM HEPES-KOH, pH 7.6 at 25 °C. 
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in the presence of 1.25% DMSO (Figure 3B).  No such decrease was observed for OAB.  
This observed decrease in absorbance at 440 nm is likely due to product inhibition, since 
2-OG could potentially mimic DAP at high concentrations, which is one of the products 
of SDAP hydrolysis.  Therefore, 1 mM 2-OG concentrations were used in all screenings 
experiments.  To further test the viability of the DapE enzyme-coupled continuous 
spectrophotometric assay a known DapE inhibitor, L-captopril, was examined (Figure 
27). L-captopril, an angiotensin-converting enzyme (ACE) inhibitor, inhibits the DapE 
from H. influenzae with an IC50 value of 3.3 μM and a measured Ki of 1.8 μM 
(competitive) 
42
 but does not inhibit LL-DAP-AT.  By monitoring the formation of DHQ 
at 440 nm in the presence of various concentrations of L-captopril in 100 mM HEPES-
KOH at pH 7.6 in  the presence of 1.25% DMSO, a clear decrease in absorbance at 440 
nm is observed as a function of L-captopril concentration.  The enzyme-coupled 
spectrophotometric assay can also be run in a discontinuous fashion.   Quenching the 
DapE reaction after 15 min with 30 mM EDTA followed by a 1 h incubation period after 
which all other reagents in 100 mM HEPES-KOH at pH 7.6 are added, is adventitious to 
remove any metal ions that might interfere with the activity of LL-DAP-AT by binding to 
DAP.  To test the discontinuous enzyme-coupled spectrophotometric assay, the DapE 
inhibitors L-captopril and L-penicillamine were investigated at various concentrations 
(Figure 28).  As the amount of L-captopril or L-penicillamine increased, the absorbance 
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Figure 27.   DapE activity and inhibition of L-captopril monitored using an 
enzymecoupled continuous spectrophotometric assay in 100 mM HEPES-KOH, pH 7.6 at 
25 °C in the presence of varying concentrations of L-captopril: 0, 50, 100, 200 and 500 
µM. 
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Figure 28.  The inhibition of  DapE using an enzyme-coupled discontinuous 
spectrophotometric assay in 100 mM HEPES-KOH, pH 7.6 at 25 °C in the presence of 
varying concentrations of (A). L-captopril: 0, 15, 50, 100, 300 and 2000 µM; and (B). L-
penicillamine: 0, 300, 500, 1000 and 3000 µM.  
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at 440 nm decreased proportionately.  These data indicate that both the continuous and 
discontinuous assays respond as expected towards the inhibition of DapE.  Therefore, this 
enzyme-coupled assay directly reflects the hydrolysis of SDAP by DapE. 
 While this enzyme-coupled continuous spectrophotometric assay for DapE 
appears promising, a viable HTS assay must discriminate between actual inhibitors and 
false positives.  Therefore, prior to large-scale HTS studies, the Z’-factor, the most 
commonly used parameter to describe the quality of an assay, was determined where a 
single 384 well plate was analyzed to assess the quality of the assay, in order to warrant  
whether the assay’s response is sufficient in comparison to control compounds.  The Z’ 
value is defined by:  
   Z’ = 1 –_3(SDcontrol+ + SDcontrol-)_   (eq. 1) 
           |meancontrol+ - meancontrol-| 
 
where SDcontrol+ and SDcontrol– represent standard deviations of the signals from positive 
and negative controls, respectively, and meancontrol+ and meancontrol–  represent the values 
corresponding to the means.
122
  The Z-factor for the DapE enzyme-coupled continuous 
spectrophotometric assay was found to be 0.89, indicating excellent separation between 
positive and negative control samples.
122
  Therefore, this DapE assay is a viable 
endpoint-type measurement mode, which allows for an increase in throughput without 
sacrificing assay quality. 
 With a viable DapE assay in hand that is amenable to HTS, the hydrolysis of 
SDAP was monitored by following the formation of DHQ at 440 nm in 100 mM HEPES-
KOH at pH 7.6 in the presence of 1.25% DMSO.  At this point, 39,072 compounds have 
been screened successfully using the HTS approach.  This productive screen provided 
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five clear hits that exhibit a >20% inhibition of DapE (Figure 29).  Unfortunately, 
inhibition studies were not viable for any of these five compounds due to their poor 
solubility in buffered aqueous solution.  Even so, four out of five compounds contained 
either a sulfonamide or sulfonyl functional group and a carbonyl moiety three to four 
atoms away.  This structural backbone is of particular interest, as sulfonamides have 
previously been shown to possess biological activity particularly as antibacterials, 
diuretics, antidiabetics, antithyroid, antihypertensive, or antiviral agents.
123
  Sulfonamides  
 
Figure 29. Compounds discovered via high-throughput screening.  
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have also attracted attention recently as the amino group can function as a metal 
ligand.
124
  Amines are commonly used as inhibitors of Zn(II) metalloproteins since Zn(II) 
is a good Lewis acid and amines serve as good Lewis bases.
110
  Therefore, it was 
hypothesized that compounds containing these groups might be involved in DapE 
inhibition by coordination to the dinuclear Zn(II) active site.  Since two out of the five 
lead compounds contain idoline sulfonamides, a structure activity relationship (SAR) 
study was undertaken based on this molecular backbone in order to identify structural 
groups that are critical for DapE recognition and binding.   
 Several indoline sulfonamide derivatives were synthesized in collaboration with 
Dr. Becker, where both X and R were varied (Figure 30).  Each of these inhibitors was 
screened using the DapE enzyme-coupled discontinuous spectrophotometric assay, and 
the percent inhibition calculated:  
 
                                      % Inhibition = (Abs0- AbsI) x 100    (eq. 2) 
                                                         Abs0 
 
where Abs0 is the absorbance in the absence of inhibitor while AbsI is the absorbance in 
the presence of inhibitor after a 3 h reaction period.   
 
 
 
 
 
 
101 
 
Figure 30.  Schematic for the idoline sulfonamides derivatives subjected to SAR studies. 
 
 
Since sulfonamides have previously been shown to be LL-DAP-AT inhibitors, as 
a control each inhibitor was also analyzed for inhibitory activity against LL-DAP-AT by 
reaction with DAP in 100 mM HEPES-KOH at pH 7.6 and monitoring the formation of 
DHQ at 440 nm.
125
  No inhibition towards LL-DAP-AT was observed for any of the 
compounds tested.  For comparison purposes, L-captopril inhibited 50% of the DapE 
activity at a concentration of 100 µM while L-penicillamine inhibited 50% of the DapE 
activity at a concentration of 500 µM.  The best inhibitors tested were 1A, 2A, 3A and 5, 
which exhibited 9.2% inhibition of the DapE hydrolysis reaction (Table 7).   
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Table 7. Percent inhibition of derivative compounds of indoline sulfonamides (± 1.5% at 
90 uM final concentrations) 
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Each of these derivatives contains a bromo-indoline group with various hydrophobic R 
groups such as piperidine, pyrrolidine cyclohexane or diethyl methoxy.  Substituting the 
R group with an isopropol (4A), aromatic ring (7A) or a bulkier dimethyl moiety (6A), or 
alkyl carboxylic acid groups (8A, 9A, 10) decreases the inhibitory ability.  Surprisingly, 
the ability of 1A, 2A, 3A and 5 to inhibit DapE is not dependent on whether the 
compound contains a secondary or tertiary amine adjacent to the sulfone functional 
group.  Therefore, the amine is unlikely serving as a ZBG, which may partially explain 
the weak affinity for DapE of these compounds.  Interestingly, simply substituting the X 
group of the indoline sulfonamide backbone from bromo to chloro (1B, 2B, 3B) 
decreases the inhibitory ability of the compounds by 30% to 83%.  Clearly the size and 
polarizability of this group is important for recognition and binding to DapE.   
 Shityakov et al. 
126
 recently published a study in which they emphasize the 
importance of structure-activity relationship studies coupled with computational 
techniques in order to analyze and confirm experimentally derived inhibitory data, since 
this approach could be a valuable tool in the future design of potent medicinal lead 
compounds.  In the absence of structural information, SWISSDock was used to explore 
potential binding modes and predict molecular interactions that may occur between DapE 
and 1A.
127
  By analyzing the free energy of binding for multiple poses, the best binding 
model was found where a sulfone oxygen atom bridges between the two Zn(II) ions with 
the indoline carbonyl moiety binding to Zn2.  An alternate pose was also explored where 
the carbonyl oxygen from the indoline ring bridges between the two zinc ions and the 
sulfone oxygen binds to Zn2 (Figure 8).  While this would be a viable binding mode to 
the dinuclear Zn(II) active site, the free energy of binding was significantly less negative.   
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Figure  31.  Docking pose for compound 1A. Color depiction: Blue: positive charge; Red: 
negative charge. 
 
 
 
Interestingly, the carbonyl oxygen atom is bound to only Zn2 while the pyrrolidine ring is 
buried deeper into a hydrophobic pocket within the active site cleft.  This binding mode is 
favorable for inhibitors with less bulky, hydrophobic R groups.  This binding pose is 
consistent with SAR data in that potential inhibitors with bulky, or hydrophilic R groups 
such as 4A, 6A, 7A, 8A, 9A, or 10 either do not inhibit DapE or are significantly weaker 
inhibitors than 1A.  It is evident from the docking simulations that the compounds with 
the best inhibitory properties interact with the active site Zn(II) ions as well as active site 
residues within a smile-shaped cleft that extends along the catalytic domain and 
surrounds the active site (Figure 31).  Therefore, linear structures without large, bulky 
Zn1 Zn2 
Active site 
cleft 
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groups and with a ZBG, such as the sulfone and/or carbonyl oxygen, would likely bind 
the best to DapE.  Such an inhibitor would also have to contain functional groups that are 
properly positioned to form hydrogen bonds with active site lysine and arginine groups, 
such as K135, R258, and R329 that reside in the smile-shaped cleft.  
 In conclusion, a rapid and reliable enzyme-coupled spectrophotometric assay for 
DapE has been developed and tested against the previously reported DapE inhibitors L-
captopril and L-penicillamine.  This enzyme-coupled spectrophotometric assay allowed 
for HTS studies to be conducted with over 39,000 compounds screened thus far providing 
five new compounds that showed >20% inhibition, providing strong verification that the 
newly developed coupled assay for DapE is selective and robust.  Four of the five newly 
identified DapE inhibitors contained a sulfone with two of the five containing an 
excellent building block, an indoline sulfonamide.  Eighteen new compounds were 
synthesized and the resulting SAR analysis indicated the importance of the sulfone, 
indoline carbonyl and bromo moieties along with a relatively small, hydrophobic group.  
Inhibitor docking studies reaffirm the importance of each of these groups and propose a 
µ-sulfone oxygen-binding mode with a terminal carbonyl oxygen atom.  These new 
medicinal chemistry lead compounds provide insight into the structural determinants of 
inhibitor binding to the active site of DapE and how active site residues can be 
advantageously targeted to improve inhibitor binding free energy.  Given that multidrug-
resistant organisms pose a serious and increasing threat to human health, it is critically 
important that new antibiotic lead compounds that target enzymes, such as DapE be 
discovered. 
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CHAPTER FIVE 
CONCLUSION 
The overall goal of this research was to obtain valuable information on the 
catalytic mechanism of DapE enzymes that might ultimately contribute in subjugating the 
problem of increasing resistance of bacteria.  The importance of this project is 
emphasized by the emergence of bacteria that are resistant to some or all currently 
available antibiotics.  This trend of increasing resistance in bacteria makes today’s 
antibiotics more and more ineffective, thus increasing the need for a new class of 
antibiotics.  One of the approaches to prevent this problem from getting out of control is 
developing drugs that target essential bacterial biosynthetic pathways.  Advances in the 
area of genomics have influenced the discovery of novel antimicrobial agents greatly.  It 
has provided the ability to scientists to identify essential genes that result in the inhibition 
of cell growth.  This approach has been very useful in selecting the meso‐
diaminopimelate (mDAP)/lysine biosynthetic pathway, which identifies DapE as a 
potential target for the development of antimicrobial agents.
26
   
In order to accomplish the research objectives in this thesis and gain insight into 
the catalytic mechanism of DapE along with the determinants of substrate/inhibitor 
binding, several biochemical and biophysical techniques were employed.  These data 
have provided essential information for rational design of DapE inhibitors, which relies 
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on understanding of the active site architecture including residues in and around the 
active site that are important for substrate recognition and binding. 
 In Chapter 1, the significance of increasing antimicrobial resistance is presented.  
Despite the critical need for new antibiotics to treat drug-resistant infections the number 
of new antibiotics approved by the FDA has been declining significantly in the past two 
decades with only five new antibiotics approved in the last few years.
17
  Fortunately, 
congress together with other health organizations have recognized this growing problem 
and raised awareness to the urgent need to develop new classes of antibiotics.  
Policymakers have offered patent extensions as well as various tax breaks, in order to 
revive interest and make antibiotic research profitable for pharmaceutical companies. 
One example of this approach is the “10 x `20” initiative, which calls for U.S. and 
European Union leaders to join forces and develop 10 novel antibiotics by 2020.
21
  This 
is just one of the examples that our government is undertaking to try and restore interest 
in antibiotic research.  Another to approach this problem is to develop drugs that target 
enzymes, such as DapE, that are present within essential bacterial biosynthetic pathways. 
This approach should yield inhibitors that may exhibit selective toxicity against bacteria 
and not humans, since there are no similar biosynthetic pathways in mammals.
27
  This 
research should contribute to benefit the health and general wellbeing of society given 
that multidrug resistant bacteria pose a serious and increasing threat to human health.   
 In Chapter 2, I examined the role of the catalytic domain of DapE by preparing 
truncated DapE enzymes by deleting the dimerization domains of the DapE from Vibrio 
cholera and H. influenzae (HiDapE
T
 and VcDapE
T
).  The resulting truncated enzymes, 
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HiDapE
T
 and VcDapE
T
, were hypothesized to be very similar to the aminopeptidase from 
Aeromonas proteolytica (AAP), which is a monomeric protein and contains a single 
catalytic domain.
88b
  Interstingly, these studies revealed that removal of the dimerization 
domain in DapE renders the enzyme inactive.  The lack of activity was quite surprising 
taking into the account that the mutants were folded properly and the overall structure 
was very similar to WT DapE.  Therefore, the truncated mutants were examined using 
molecular dynamic, X-ray crystallographic, and mutagenesis methods to understand why 
they were inactive.  Analysis of the X-ray crystal structures of HiDapE
T
 and VcDapE
T
 
revealed that loop V is much more flexible in the truncated enzymes than WT-DapE due 
to the lack of interactions provided by the dimerization domain.  These data suggest that 
the dimerization domain restricts the conformational freedom of the loop V region and 
may contribute residues to the active site environment that are important for substrate 
recognition and binding.  Molecular Dynamic simulations, which were consistent with 
the crystallographic data, showed that the truncated proteins have greater flexibility in the 
loop created to replace the dimerization domain and also in the active site loop V. 
Mutation of T325, a residue that resides on loop V and is positioned directly above the 
dinuclear active site forming a hydrogen bond with the bridging water molecule, 
confirmed that the position of loop V is important for the proper organization of active 
site residues, which are directly to catalysis.
119
  Moreover, these data suggested that 
designing small molecules inhibitors that interact with this active site loop V region as 
well as the dinuclear metal center might lead to potent DapE inhibitors that can function 
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as antibacterial agents. Disrupting dimer formation may also be an avenue to explore for 
the development of potent DapE inhibitors.   
In Chapter 3, I investigated the inhibition of L-captopril on the DapE enzymes 
from H. influenzae and N. meningitidis.  Previous studies have shown that L-captopril is a 
competitive inhibitor of the DapE from H. influenzae (Ki = 3.3µM).
42
  L-captopril was 
found to also be a competitive inhibitor of the DapE form N. meningitidis (Ki = 2.8 μM). 
The electronic properties of the Co(II)-forms of DapE bound by L-captopril was 
examined using electronic absorption, EPR, and MCD spectroscopies.  In the presence of 
L-captopril, UV-Vis spectra of Co(II)-substituted DapE enzymes revealed a red-shift in 
the λmax of ~30 nm along with an increase in molar absorptivity, suggesting that L-
captopril interacts with both metal ions in the dinuclear active site.  EPR and MCD data 
indicate that the Co(II) ions in [Co_DapE] and [CoCoDapE] are five- and six-coordinate, 
respectively and are weakly antiferromagnetically coupled upon the addition of L-
captopril yielding an S = 0 ground state.  These data confirm that L-captopril interacts 
with both metal ions residing within the active site of DapE and suggest that the thiolate 
of L-captopril bridges between the two metal ions.  Conformation of this proposed 
structure was derived from EXAFS and X-ray crystallography.  EXAFS data clearly 
indicate the coordination of a thiolate to the dinuclear Zn(II) center of DapE with an 
increase in the Zn-Zn distance, suggesting a bridging thiolate.  The three-dimensional 
structure of the DapE from N. meningitidis bound by L-captopril was solved to 1.78 Å. 
This is the first structure of any DapE enzyme bound by an exogenous molecule.  The 
structure reveals that the thiolate of L-captopril does, in fact, bridge between the two 
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Zn(II) ions consistent with the EPR, MCD, and EXAFS data.  The results obtained in this 
study provide new insight into the important determinants of inhibitor binding including 
active site residues that form hydrogen-bonding interactions.  These data are crucial for 
the rational design and synthesis of potent DapE inhibitors. 
 In Chapter 4, new medicinal chemistry lead compounds for DapE enzymes were 
discovered through high-throughput screening (HTS) studies.  In order to perform HTS, 
an enzyme-coupled continuous spectrophotometric assay for DapE was designed and 
developed.  The hydrolysis of N-succinyl-L,L-diaminopimelic acid (SDAP) was coupled 
to L,L-diaminopimelate aminotransferase (LL-DAP-AT), which can utilize DAP as an 
amino donor and 2-oxoglutarate (2-OG) as an amino acceptor, to produce 
tetrahydrodipicolinate (THDP) that when coupled with 2-aminobenzaldehyde (OAB) 
produces dihydroquinazolium (DHQ), which absorbs at 440 nm.  Extensive testing of this 
assay proved that it was dependent on the hydrolysis reaction catalyzed by DapE.  With a 
viable spectrophotometric assay in hand for DapE, HTS was carried out at the Chemical 
Genomics Core Facility at Indiana University School of Medicine in collaboration with 
Professor Ye.  More than 39,000 compounds were screened with five inhibiting DapE 
activity by >20 %, which is a strong verification that the newly developed coupled assay 
for DapE is selective and robust.  Four of these compounds contained either sulfonamide 
or sulfonyl functional groups, which have not been explored previously as DapE 
inhibitors.  A discontinuous form of this enzyme-coupled assay was also developed to 
test the inhibition of eighteen newly synthesized sulfonamide derivatives by determining 
the percent inhibition.  Four of the newly synthesized compounds proved to be moderate 
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inhibitors of DapE.  Finally, the best inhibitor was docked into the active site to analyze 
the important inhibitor-enzyme interactions for the design of new, more potent DapE 
inhibitors. 
 The completion of this research provided insight into the determinants of 
substrate/inhibitor binding to DapE.   In addition, new medicinal chemistry lead 
compounds were discovered and studies were conducted to gains an understanding of 
their mode of binding to DapE.  These data are critical to future studies on the design and 
synthesis of highly‐selective inhibitors of DapE.  The discovery of such inhibitors will 
potentially provide a novel class of antibiotics, which are desperately needed to fight the 
spread of infectious disease. 
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